



(19)

Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11)

**EP 1 344 820 A1**

(12)

**EUROPEAN PATENT APPLICATION**  
published in accordance with Art. 158(3) EPC

(43) Date of publication:  
17.09.2003 Bulletin 2003/38

(21) Application number: **01997189.4**

(22) Date of filing: **21.11.2001**

(51) Int Cl.7: **C12N 9/42, C11D 3/386,  
D06M 16/00, C12R 1/645,  
C12N 1/15, D06M 101/06**

(86) International application number:  
**PCT/JP01/10188**

(87) International publication number:  
**WO 02/042474 (30.05.2002 Gazette 2002/22)**

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE TR**  
Designated Extension States:  
**AL LT LV MK RO SI**

(30) Priority: **21.11.2000 JP 2000354296**

(71) Applicant: **Meiji Seika Kaisha, Ltd.**  
**Tokyo 104-8002 (JP)**

(72) Inventors:  
• **NAKANE, Akitaka, c/o Meiji Seika Kaisha, Ltd.**  
**Sakado-shi, Saltama 350-0289 (JP)**

• **BABA, Yuko, c/o Meiji Seika Kaisha, Ltd.**  
**Sakado-shi, Saltama 350-0289 (JP)**  
• **KOGA, Jinichiro, c/o Meiji Seika Kaisha, Ltd.**  
**Sakado-shi, Saltama 350-0289 (JP)**  
• **KUBOTA, Hidetoshi, c/o Meiji Seika Kaisha, Ltd.**  
**Sakado-shi, Saltama 350-0289 (JP)**

(74) Representative: **Gillard, Richard Edward**  
**Elkington and Fife**  
**Prospect House**  
**8 Pembroke Road**  
**Sevenoaks**  
**Kent TN13 1XR (GB)**

**(54) ZYGOMYCETES-ORIGIN ENDOGLUCANASE LACKING CELLULOSE-BINDING DOMAIN**

(57) This invention relates to a protein that is a *Zygomycetes*-derived endoglucanase lacking the cellulose-binding domain and exhibits endoglucanase activity, and a method for using the same. This invention can enhance effects of an endoglucanase enzyme on fabric treatment such as reduction of fuzzing, improvement in

feel and appearance, color clarification, partial color change, and softening of cellulose-containing fabrics and on performance improvement in the deinking of waste paper and drainage of paper pulp.

**EP 1 344 820 A1**

**Description**Technical Field

- 5 **[0001]** The present invention relates to an endoglucanase enzyme, the cellulose-binding domain of which has been deleted, with enhanced effects in the treatment of cellulose-containing fabrics and with applications regarding detergents or paper pulp, a method for producing the same, and a cellulase preparation with enhanced effects.

Background Art

- 10 **[0002]** Treatment of cellulose-containing fabrics with cellulase is carried out to provide the fabrics with desired properties. For example, treatment with cellulase is carried out in the fabric industry in order to improve the feel and appearance of cellulose-containing fabrics or to give colored cellulose-containing fabrics an appearance of "stone-washed" material, i.e., partial color change (European Patent No. 307,564).
- 15 **[0003]** Colored cellulose-containing fabrics are known to become fuzzy after repeated washings and to lose their vividness. Incorporation of cellulase into a detergent can remove fuzz and make the color of fabrics vivid, i.e., clarify the color (European Patent No. 220,016). Thus, detergents containing cellulase are commercially available mainly in Europe and America.
- 20 **[0004]** In the aforementioned application, cellulases derived from *Trichoderma* or *Humicola* (both are wood-rotting fungi) are mainly used. Recently used cellulase preparations are produced by isolating endoglucanases, which are highly active in fabric treatment, from these cellulase components and enhancing their effects with genetic engineering in order to improve commercial efficiency. Examples of these highly active endoglucanases include: *Humicola insolens*-derived EG V (WO 91/17243) and NCE4 (WO 98/03640) that strongly act on cotton fabrics; and *Rhizopus oryzae*-derived RCE I, RCE II, and RCE III, *Mucor circinelloides*-derived MCE I and MCE II, and *Phycomyces nitens*-derived
- 25 PCE I (WO 00/24879) that strongly act on lyocell fabrics.
- [0005]** Among endoglucanases used in the aforementioned applications, EG V (WO 91/17243), NCE4 (WO 98/03640), and RCE I, RCE II, RCE III, MCE I, MCE II, and PCE I (WO 00/24879) are presumed to belong to the same family (family 45) because of their amino acid sequences, and these enzymes have common structural properties. Specifically, each of these endoglucanases comprises a cellulose-binding domain for binding to cellulose as its substrate (hereinafter referred to as "CBD"), a catalytic active domain as an active center (hereinafter referred to as "CAD"), and a linker domain with a high hydrophilic amino acid residue content for linking these two domains.
- 30 **[0006]** EG V, an endoglucanase belonging to family 45, was studied using an enzyme, the CBD domain of which had been deleted (JP Patent Publication (PCT Translation) No. 9-500667, Enzyme and Microbial Technology, 27 (2000), 325-329). However, no improvement has been reported regarding the activity of endoglucanase for removing fuzz from cellulose fabrics through the deletion of the cellulose-binding domain (CBD). There are still many unclarified matters concerning the role of the cellulose-binding domain of endoglucanase in the exhibition of endoglucanase activity, and research thereof is limited to cellulase derived from a specific fungus, namely, *Trichoderma* (Kioyula, A. et al., *Trichoderma Gliocladium*, 2, (1998), 3-23). There has been no detailed research on the cellulose-binding domain of the *Zygomycetes*-derived endoglucanase.
- 35 **[0007]** Up to the present, several contrivances have been made in order to improve the effect or performance of cellulase in the above applications. For example, mutation was applied to an enzyme for improvement thereof, or culture conditions were modified in order to improve the productivity of the enzyme. Due to the high cost of cellulase to be used, however, the effect of cellulase should be further improved in order to provide a cellulase preparation that is worth using at an industrially practical level. Recently used cellulase preparations are produced by reinforcing only
- 40 endoglucanase, which is highly active in fabric treatment, with genetic engineering in order to improve commercial efficiency. Accordingly, it is desirable to further improve the activity of such highly active cellulase.
- 45

Disclosure of the Invention

- 50 **[0008]** An object of the present invention is to provide an endoglucanase with improved activity, a cellulase preparation comprising the same, and various methods for treating cellulose-containing fabrics using the same.
- [0009]** The present inventors have conducted concentrated studies on the *Zygomycetes*-derived endoglucanase concerning the role of a cellulose-binding domain when acting on cellulose-containing fabrics. As a result, they have found that an endoglucanase lacking the cellulose-binding domain has much higher activity of removing fuzz from
- 55 cotton, lyocell, or the like compared to an endoglucanase having a cellulose-binding domain. This led to the completion of the present invention.
- [0010]** Specifically, the present invention relates to a *Zygomycetes*-derived endoglucanase that has enhanced effects for removing fuzz from cellulose-containing fabrics (e.g., an enzyme comprising amino acid sequences of RCE I, RCE

II, RCE III, MCE I, MCE II, and PCE I, which attained enhanced effects of removing fuzz from cellulose-containing fabrics through the deletion of the cellulose-binding domain, and exhibiting endoglucanase activity, a modified protein thereof exhibiting endoglucanase activity, or a homologue of the protein or the modified protein) and a cellulase preparation comprising such endoglucanase. The present invention also relates to an endoglucanase that was produced in a host cell transformed with a gene encoding such an endoglucanase, and further relates to a method for treating cellulose-containing fabrics using the endoglucanase, which attained improved activity through the deletion of the cellulose-binding domain, or the cellulase preparation.

[0011] More specifically, the present invention includes the following.

- (1) A protein that is a *Zygomycetes*-derived endoglucanase lacking the cellulose-binding domain and exhibits endoglucanase activity.
- (2) A protein that is a *Zygomycetes*-derived endoglucanase belonging to family 45 lacking the cellulose-binding domain and exhibits endoglucanase activity.
- (3) The protein according to (1) or (2), wherein the *Zygomycetes* are microorganisms selected from the group consisting of those belonging to *Rhizopus*, *Mucor*, and *Phycomyces*.
- (4) The protein according to (3), wherein the *Zygomycetes* are microorganisms belonging to *Rhizopus*.
- (5) A protein comprising an amino acid sequence as shown in SEQ ID NO: 1, 3, 5, 7, 9, or 11, wherein the cellulose-binding domain has been deleted therefrom, and exhibiting endoglucanase activity, a modified protein thereof exhibiting endoglucanase activity, or a homologue of the protein or the modified protein exhibiting endoglucanase activity.
- (6) A protein comprising an amino acid sequence as shown in SEQ ID NO: 1, 3, 5, 7, 9, or 11, wherein the cellulose-binding domain has been deleted therefrom, and exhibiting endoglucanase activity.
- (7) A gene encoding the protein, modified protein thereof, or homologue of the protein or the modified protein according to any one of (1) to (6).
- (8) An expression vector comprising the gene according to (7).
- (9) A host cell transformed with the expression vector according to (8).
- (10) The host cell according to (9), which is a filamentous fungus.
- (11) The host cell according to (10), which is a microorganism belonging to *Humicola*.
- (12) A method for producing a protein comprising steps of culturing the host cell according to any one of (9) to (11) and collecting from the host cell obtained by the step of culturing or its culture product the protein, modified protein thereof, or homologue of the protein or the modified protein according to any one of (1) to (6).
- (13) A protein produced by the method according to (12).
- (14) A cellulase preparation comprising the protein, modified protein thereof, or homologue of the protein or the modified protein according to any one of (1) to (6) and (13).
- (15) A method for treating cellulose-containing fabrics comprising a step of bringing cellulose-containing fabrics into contact with the protein, modified protein thereof, or homologue of the protein or the modified protein according to any one of (1) to (6) and (13) or the cellulase preparation according to (14).
- (16) A method for reducing the rate at which cellulose-containing fabrics become fuzzy or reducing fuzzing in cellulose-containing fabrics comprising a step of bringing cellulose-containing fabrics into contact with the protein, modified protein thereof, or homologue of the protein or the modified protein according to any one of (1) to (6) and (13) or the cellulase preparation according to (14).
- (17) A method of weight loss treatment of cellulose-containing fabrics to improve the feel and appearance thereof comprising a step of bringing cellulose-containing fabrics into contact with the protein, modified protein thereof, or homologue of the protein or the modified protein according to any one of (1) to (6) and (13) or the cellulase preparation according to (14).
- (18) A method of color clarification of colored cellulose-containing fabrics comprising a step of treating colored cellulose-containing fabrics with the protein, modified protein thereof, or homologue of the protein or the modified protein according to any one of (1) to (6) and (13) or the cellulase preparation according to (14).
- (19) A method of providing colored cellulose-containing fabrics with partial color change comprising a step of treating colored cellulose-containing fabrics with the protein, modified protein thereof, or homologue of the protein or the modified protein according to any one of (1) to (6) and (13) or the cellulase preparation according to (14).
- (20) A method for reducing the rate at which cellulose-containing fabrics become stiff or reducing stiffness in cellulose-containing fabrics comprising a step of treating cellulose-containing fabrics with the protein, modified protein thereof, or homologue of the protein or the modified protein according to any one of (1) to (6) and (13) or the cellulase preparation according to (14).
- (21) The method according to any one of (15) to (20), wherein fabrics are treated through soaking, washing, or rinsing thereof.
- (22) An additive to detergent comprising the protein, modified protein thereof, or homologue of the protein or the

modified protein according to any one of (1) to (6) and (13) or the cellulase preparation according to (14) in a non-dusting granular form or a stabilized liquid form.

(23) A detergent composition comprising the protein, modified protein thereof, or homologue of the protein or the modified protein according to any one of (1) to (6) and (13) or the cellulase preparation according to (14).

5 (24) A method of deinking waste paper using a deinking agent wherein the protein, modified protein thereof, or homologue of the protein or the modified protein according to any one of (1) to (6) and (13) or the cellulase preparation according to (14) is used in a step of deinking waste paper.

(25) A method for improving drainage of paper pulp comprising a step of treating paper pulp with the protein, modified protein thereof, or homologue of the protein or the modified protein according to any one of (1) to (6) and  
10 (13) or the cellulase preparation according to (14).

(26) A method for improving digestibility of animal feeds comprising a step of treating animal feeds with the protein, modified protein thereof, or homologue of the protein or the modified protein according to any one of (1) to (6) and (13) or the cellulase preparation according to (14).

# 15 1. Endoglucanase lacking cellulose-binding domain

**[0012]** The present invention relates to a protein that is a *Zygomycetes*-derived endoglucanase lacking the cellulose-binding domain and exhibits endoglucanase activity.

20 **[0013]** In this description, "*Zygomycetes*" refer to microorganisms belonging to *Zygomycota*, i.e., fungi that generate zygospores through gametangial copulation upon gametogony. The *Zygomycota* includes *Zygomycetes* and *Trichomycetes*. The *Zygomycetes* used in the present invention are not particularly limited. Microorganisms belonging to the *Zygomycetes* are preferable, those belonging to the *Mucorales* are more preferable, those belonging to *Rhizopus*, *Mucor*, or *Phycomyces* are still more preferable, and those belonging to the *Rhizopus* are the most preferable.

25 **[0014]** In this description, "endoglucanase activity" refers to CMCase activity. Further, "CMCase activity" refers to an activity for hydrolyzing carboxymethylcellulose (CMC, Tokyo Kasei Kogyo, Japan), and one unit is defined as the amount of an enzyme which produces reducing sugars corresponding to 1  $\mu$ mol of glucose per minute by measuring amounts of the reducing sugars released after incubation of a test protein with a CMC solution for a given period of time.

30 **[0015]** Endoglucanase activity can be determined by, for example, a procedure as described below. At the outset, 0.5 ml of a solution containing a test protein is added to 0.5 ml of 50 mM acetic acid-sodium acetate buffer solution (pH 6.0) with 2% CMC dissolved therein, and the mixture is subjected to incubation at 50°C for 30 minutes. Subsequently, the concentration of the reducing sugars produced in the resulting reaction solution is quantified by the 3,5-dinitrosalicylic acid (DNS) method. Specifically, 3.0 ml of a DNS reagent is added to 1.0 ml of the reaction solution 30 minutes after the reaction, and the mixture is subjected to incubation in a boiling water bath for 5 minutes. Thereafter, the incubation product is diluted with 8.0 ml of distilled water, and the absorbance at 540 nm is measured. A calibration  
35 curve is prepared using a gradually diluted glucose solution, and the amount of the reducing sugars produced in the enzyme reaction solution is determined. Activity is determined using an amount of the enzyme that produces reducing sugars corresponding to 1  $\mu$ mol glucose per minute as one unit. This DNS reagent can be prepared in accordance with publication such as Seibutsu Kagaku Jikkenhou 1 - Kagentou no Teiryohou (Biochemical Experimentation 1- The method for quantifying reducing sugar) (p. 19-20, Sakuzo Fukui, Center for Academic Publications Japan), and  
40 can be prepared in the manner described below. At the outset, 880 ml of 1% 3,5-dinitrosalicylic acid solution and 255 g of Rochelle salt are added to 300 ml of an aqueous solution of 4.5% sodium hydroxide (solution A). Separately, 10 g of crystalline phenol is added to 22 ml of an aqueous solution of 10% sodium hydroxide, and water is further added and dissolved in the mixture to bring the amount thereof to 100 ml (solution B). Sodium bicarbonate (6.9 g) is added to 69 ml of solution B and dissolved therein, solution A is poured therein, and the mixture is stirred and mixed until the  
45 Rochelle salt is thoroughly dissolved. The mixture is allowed to stand for 2 days and then filtered.

**[0016]** The term "endoglucanase" used herein refers to an enzyme exhibiting endoglucanase activity, i.e., endo-1,4- $\beta$ -glucanase (EC 3. 2. 1. 4). This enzyme hydrolyzes the  $\beta$ -1,4-glucopyranosyl bond of  $\beta$ -1,4-glucan.

50 **[0017]** Endoglucanases are classified into several families based on information such as their amino acid sequences. The endoglucanase according to the present invention may belong to any family, and it preferably belongs to family 45. The endoglucanase "belonging to family 45" refers to those types having a consensus sequence, (Ser, Thr, or Ala)-Thr-Arg-Tyr-(Trp, Tyr, or Phe)-Asp-Xaa-Xaa-Xaa-Xaa-Xaa-(Cys or Ala), in the catalytic active domain (CAD). *Humicola* insolens-derived EG V (JP Patent Publication (PCT Translation) No. 5-509223), NCE4 (WO 98/03640), and the like also belong to family 45.

55 **[0018]** A protein of endoglucanase belonging to family 45 is comprised a catalytic active domain (CAD), a cellulose-binding domain (CBD), and a linker domain for linking based on function. The cellulose-binding domain (CBD) is known to exist as a domain linking to cellulose as its name suggests, and the conservation of the following consensus sequence is confirmed as a feature of the sequence (Hoffren, A. -M. et al., Protein Engineering 8: 443-450, 1995).

CBD consensus sequence:

1  
 Xaa Xaa Xaa Xaa Xaa Xaa Gln Cys Gly Gly Xaa Xaa Xaa Xaa  
 20  
 Gly Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa  
 30  
 Xaa Xaa Xaa Asn Xaa Xaa Tyr Xaa Gln Cys Xaa (SEQ ID NO: 17)

[0019] In this sequence, Xaa is independently any amino acid; and Xaas at positions 20, 21, 22, 23, 24, 30 and 31 may be independently absent. Other Xaas are always present and are independently any amino acids. Amino acids other than Xaa are expressed in three-letter abbreviations. CBD is linked to either the N-terminal side or C terminal side of CAD through a linker domain. Also reported is *Humicola insolens*-derived NCE5 (amino acid sequence: SEQ ID NO: 38, cDNA sequence: SEQ ID NO. 39) such as a family 45 endoglucanase that does not originally have CBD.

[0020] Although there is no definite recognition sequence for the linker domain, the sequence is rich in hydrophilic amino acid residues such as Ser or Thr, and its length varies depending on types of endoglucanases.

[0021] Examples of the *Zygomycetes*-derived endoglucanase according to the present invention include enzymes exhibiting endoglucanase activity derived from *Rhizopus*, *Phycomyces*, or *Mucor* described in WO 00/24879, i.e., RCE I (SEQ ID NO: 1), RCE II (SEQ ID NO: 3), RCE III (SEQ ID NO: 5), MCE I (SEQ ID NO: 7), MCE II (SEQ ID NO: 9), and PCE I (SEQ ID NO: 11). Locations of each of the domains in the amino acid sequence of these enzymes are as shown in Table 1 below.

Table 1

	CBD	A portion in linker domain	CAD
SEQ ID NO: 1	3 to 38	99 to 108	109 to 315
SEQ ID NO: 3	3 to 38	127 to 136	137 to 343
	50 to 85		
SEQ ID NO: 5	3 to 40	122 to 131	132 to 337
SEQ ID NO: 7	3 to 40	104 to 113	114 to 316
SEQ ID NO: 9	3 to 40	153 to 162	163 to 365
	52 to 89		
SEQ ID NO: 11	3 to 40	115 to 124	125 to 327

[0022] Amino acid sequences at the N-terminuses of RCE I, MCE I, and PCE I are respectively identified as shown in SEQ ID Nos: 14, 15, and 16 (WO 00/24879).

[0023] The protein according to the present invention should not comprise a cellulose-binding domain in the aforementioned endoglucanase. As long as the protein has endoglucanase activity, there is no particular limitation on the structure of other domains. Accordingly, the protein of the present invention may or may not comprise a linker domain. The protein may alternatively comprise a portion of a linker domain, and it is preferable if the protein retains a fragment of a linker domain comprising about 10 amino acid residues.

[0024] The other aspect of the present invention relates to a protein comprising any of the amino acid sequences as shown in SEQ ID NO: 1 (RCE I), SEQ ID NO: 3 (RCE II), SEQ ID NO: 5 (RCE III), SEQ ID NO: 7 (MCE I), SEQ ID NO: 9 (MCE II), or SEQ ID NO: 11 (PCE I), wherein the cellulose-binding domain has been deleted therefrom, and exhibiting endoglucanase activity. The present invention further relates to a modified protein and a homologue of such protein exhibiting endoglucanase activity.

[0025] In this description, the term "modified protein" refers to a protein that comprises an amino acid sequence having modification such as addition, insertion, diminution, deletion, or substitution of one or several amino acids in the amino acid sequence of RCE I, RCE II, RCE III, MCE I, MCE II, or PCE I, which lacks the cellulose-binding domain. The number of the amino acids to be involved with such modification is not particularly limited as long as the modified

protein has endoglucanase activity. The number thereof is preferably 1 to about 50, more preferably 1 to about 30, and still more preferably 1 to 9.

[0026] The term "homologue" used herein refers to a polypeptide having an amino acid sequence coded by a gene encoding the amino acid sequences of RCE I, RCE II, RCE III, MCE I, MCE II, and PCE I lacking the cellulose-binding domain. One example would be a gene (nucleotide sequence) that hybridizes under stringent conditions with DNA having any nucleotide sequence as shown in SEQ ID NO: 2 or 13 (RCE I), SEQ ID NO: 4 (RCE II), SEQ ID NO: 6 (RCE III), SEQ ID NO: 8 (MCE I), SEQ ID NO: 10 (MCE II), or SEQ ID NO: 12 (PCE I), wherein a portion encoding a cellulose-binding domain has been removed and having endoglucanase activity. The term "stringent conditions" refers to conditions under which, while a probe that comprises the nucleotide sequence encoding a part or all of the amino acid sequences of RCE I, RCE II, RCE III, MCE I, MCE II, and PCE I lacking the cellulose-binding domain or an amino acid sequence of its modified protein hybridizes with a gene encoding a homologue, this probe is controlled to such an extent that it does not hybridize with the endoglucanase NCE4 gene (SEQ ID NO: 18) according to WO 98/03640 or the endoglucanase SCE3 gene (SEQ ID NO: 19) according to WO 98/54332 (wherein the amount of DNA used is equal to that of the gene encoding the NCE4 gene, SCE3 gene, or a homologue). A specific example of "stringent conditions" is as follows. A labeled probe having a full length DNA sequence encoding amino acid sequences such as RCE I, which lacks the cellulose-binding domain, is used. In accordance with the method of the ECL Direct DNA/RNA Labeling Detection System (Amersham), prehybridization is carried out at 42°C for 1 hour, the probe is added, and hybridization is then carried out at 42°C for 15 hours. Thereafter, 0.5x SSC (1x SSC; 15 mM trisodium citrate, 150 mM sodium chloride) comprising 0.4% SDS and 6M urea is used to perform washing twice at 42°C for 20 minutes. Subsequently, 5x SSC is used to perform washing twice at room temperature (about 25°C) for 10 minutes.

[0027] Examples of such modified proteins or homologue include a protein having an amino acid sequence that is preferably at least 70%, more preferably at least 80%, still more preferably at least 90%, even more preferably at least 95%, and most preferably at least 98% homologous to the amino acid sequence of RCE I, RCE II, RCE III, MCE I, MCE II, or PCE I, which lacks the cellulose-binding domain. The numerical values indicating homology may be determined using a program for searching for homology that is known to a person skilled in the art. Preferably, these numerical values are determined using default (initial setting) parameters at FASTA3 (Science, 227, 1435-1441 (1985); Proc. Natl. Acad. Sci. USA, 85, 2444-2448 (1988); <http://www.ddbj.nig.ac.jp/E-mail/homology-j.html>).

[0028] The protein of the present invention does not comprise a cellulose-binding domain. Accordingly, the modified protein and the homologue should not comprise a cellulose-binding domain. This can be confirmed by investigating the amino acid sequence of the object protein and whether or not the consensus sequence (Hoffren, A. -M. et al., Protein Engineering 8: 443-450, 1995; SEQ ID NO: 17) is present therein.

[0029] Also, the protein of the present invention has endoglucanase activity. Accordingly, the modified protein and the homologue should also have endoglucanase activity. This can be confirmed by investigating endoglucanase activity of the object protein by the aforementioned method.

[0030] The protein of the present invention can be produced as a protein comprising an amino acid sequence that does not comprise a cellulose-binding domain by a method known to a person skilled in the art based on the amino acid sequence of a known endoglucanase derived from *Zygomycetes*. Examples of such a method include a method that is carried out by decomposing in a linker domain using protease during the culture of *Zygomycetes* producing endoglucanase to cause deletion of the cellulose-binding domain and a method that is carried out by artificially expressing endoglucanase that does not have a cellulose-binding domain due to genetic engineering techniques. Among the proteins of the present invention, in particular, the modified protein and the homologue can be prepared using DNA encoding their amino acid sequences by a genetic engineering technique that is known to a person skilled in the art.

[0031] The protein of the present invention can yield a higher effect than the original endoglucanase having a cellulose-binding domain in fabric treatment or other applications to detergents or paper pulp. Particularly, a much higher effect can be attained in the activity of removing fuzz from reproduced cellulose fabric such as lyocell (per protein weight) and in the activity of removing fuzz from cotton fabric such as knitted cotton (per protein weight). The protein of the present invention is preferably twice or higher, more preferably 2.5 times or higher, and most preferably 3 times or higher in the activity of removing fuzz from reproduced cellulose fabric (such as lyocell) (per protein weight) as a purified endoglucanase having the cellulose-binding domain. Or, the protein is preferably 5 times or higher, more preferably 15 times or higher, and most preferably 20 times or higher in the activity of removing fuzz from cotton fabric such as knitted cotton (per protein weight) as a purified endoglucanase having the cellulose-binding domain.

## 2. Gene, expression vector, host cell transformed with the expression vector, and production of endoglucanase lacking the cellulose-binding domain using the host cell

[0032] The present invention relates to a gene encoding the protein of the present invention, a modified protein thereof, or a homologue of the protein or the modified protein and an expression vector comprising the gene.

[0033] The gene of the present invention may be any gene as long as it encodes the protein of the present invention,

a modified protein thereof, or a homologue of the protein or the modified protein. Specific details of their nucleotide sequences are not particularly limited. Examples of usable genes in order to express RCE I, RCE II, RCE III, MCE I, MCE II, or PCE I, which lacks the cellulose-binding domain, as the protein of the present invention include those comprising nucleotide sequences as shown in SEQ ID NO: 2 (RCE I), SEQ ID NO: 4 (RCE II, SEQ ID NO: 6 (RCE III),  
 5 SEQ ID NO: 8 (MCE I), SEQ ID NO: 10 (MCE II), or SEQ ID NO: 12 (PCE I).

**[0034]** Specifically, the gene of the present invention comprises an amino acid sequence as shown in SEQ ID NO: 1, 3, 5, 7, 9, or 11, wherein the cellulose-binding domain has been deleted therefrom, and encodes a protein exhibiting endoglucanase activity, a modified protein thereof exhibiting endoglucanase activity, or a homologue of the protein or the modified protein exhibiting endoglucanase activity.

10 **[0035]** The gene of the present invention comprises DNA as described in the following (a) or (b).

(a) DNA that has a nucleotide sequence as shown in SEQ ID NO: 2 or 13, 4, 6, 8, 10, or 12, wherein a portion encoding a cellulose-binding domain has been deleted therefrom.

15 (b) DNA that hybridizes under stringent conditions with DNA that has a nucleotide sequence as shown in SEQ ID NO: 2 or 13, 4, 6, 8, 10, or 12, wherein a portion encoding a cellulose-binding domain has been deleted therefrom.

**[0036]** The term "stringent conditions" means the conditions described in the section 1. above.

**[0037]** The nucleotide sequences of the aforementioned genes can be optimized depending on the type of host cell used in the later transformation. These nucleotide sequences can be optimized with respect to, for example, the codon usage in a host cell or the intron recognition sequence in a host cell. The codon usage can be optimized by, for example, modifying nucleotide sequences so as to comprise as many codons used in a host cell at high frequency as possible without changing the amino acid sequence to be coded. This can improve the efficiency of translation from genes into proteins. The intron recognition sequence can be optimized by, for example, modifying nucleotide sequences so as to have no DNA sequence, which could be recognized as an intron in a host cell, or to have as few sequences as possible without changing the amino acid sequence to be coded. This can improve the stability of mRNA that is a transcript of an object gene. The intron recognition sequences vary depending on types of host cells. Examples of intron recognition sequences of filamentous fungi belonging to the Fungi imperfecti include DNA sequences such as GTAGN, GTATN, GTAAN, GTACGN, GTGTN, GCACGN, and GTTCGN ("N" stands for A, T, C, or G in each sequence).

**[0038]** In this description, the term "codon optimized gene" refers to a gene that is obtained by optimizing the codon usage and/or the intron recognition sequence. Preferably, the codon optimized gene is a gene obtained by optimizing the codon usage, and more preferably a gene obtained by optimizing the codon usage and the intron recognition sequence. This codon optimized gene is preferably optimized for the expression in filamentous fungi belonging to the Fungi imperfecti. Examples of such codon optimized genes include a gene which lacks a portion encoding a cellulose-binding domain in the codon optimized endoglucanase RCE I gene (SEQ ID NO: 13) as disclosed in WO 00/24879.

35 **[0039]** The expression vector of the present invention comprises an object gene (a gene encoding the protein of the present invention, a modified protein thereof, or a homologue of the protein or the modified protein) in a state that is replicable in a host cell and expressible of the protein of the present invention, a modified protein thereof, or a homologue of the protein or the modified protein. This expression vector can be constructed based on a self-replicating vector, i. e., a vector that exists as an extrachromosomal entity and replicates independently of the chromosome, for example, a plasmid. Alternatively, the expression vector may be a vector that is integrated into the genome of the host cell upon introduction thereto and replicated together with the chromosome into which it has been incorporated. For the construction of the vector of the present invention, conventional procedures and methods used in the field of genetic engineering can be used.

40 **[0040]** For the expression of the protein of the present invention, a modified protein thereof, or a homologue of the protein or the modified protein upon introduction into the host cell, it is desirable that the expression vector of the invention contains DNA sequences to regulate the expression and gene markers, etc. to select transformants, in addition to the gene encoding the protein of the present invention, a modified protein thereof, or a homologue of the protein or the modified protein. Examples of expression regulatory DNA sequences include promoters, terminators, and DNA sequences encoding signal peptides. The promoters and the terminators are not particularly limited as long as they show transcription activity in the host cell. They may be obtained as DNA sequences, which control the expression of a gene encoding a protein homogeneous or heterogeneous to the host cell. The signal peptides are not particularly limited as long as they contribute to the secretion of protein in the host cell. They may be obtained from DNA sequences derived from a gene encoding a protein homogeneous or heterogeneous to the host cell. The gene markers of the invention can be appropriately selected depending on the method for selecting transformants. For example, genes encoding drug resistance or genes complementing auxotrophy may be used. Each of these DNA sequences and gene markers is operably linked to the expression vector of the present invention.

55 **[0041]** Further, the present invention relates to a host cell that is transformed with the expression vector. The expression vector introduced into a host cell should be replicable therein. Thus, the host cell that is used herein varies

depending on the type of vector used in the production of the expression vector. Alternatively, in accordance with the type of a host cell to be used, an expression vector can be produced so as to be replicable therein. Specifically, in order to obtain a transformant that expresses the protein of the present invention, a modified protein thereof, or a homologue of the protein or the modified protein, a host cell and an expression vector should be adequately combined. Such a combination is referred to as a host-vector system. The host-vector system that is used in the present invention is not particularly limited. Examples thereof include systems using microorganisms such as *Escherichia coli*, *Actinomyces*, yeast, and filamentous fungi as host cells, and a system using filamentous fungi is preferred. An expression system for a fusion protein with other protein can be also used.

[0042] When filamentous fungi are used as host cells, any type of filamentous fungi can be used, and preferred examples thereof include those belonging to *Humicola*, *Aspergillus*, or *Trichoderma*. Particularly preferred examples of these filamentous fungi include *Humicola insolens*, *Aspergillus niger* or *Aspergillus oryzae*, and *Trichoderma viride*.

[0043] A host cell can be transformed with the expression vector of the present invention in accordance with conventional methods used in the field of genetic engineering.

[0044] The thus obtained transformant (transformed host cell) is cultured in a suitable medium, and the protein of the present invention, a modified protein thereof, or a homologue of the protein or the modified protein can be isolated and obtained from the culture product. Accordingly, another aspect of the present invention relates to a method for producing a protein comprising steps of culturing the host cell of the present invention and collecting the protein of the present invention, a modified protein thereof, or a homologue of the protein or the modified protein from the host cell obtained by the step of culture or a culture product thereof. Culture methods and other conditions for transformants may be substantially the same as those for microorganisms to be used. The transformants can be cultured and the object protein can be then collected by a conventional method of this technical field.

### 3. Cellulase preparation

[0045] The present invention relates to a cellulase preparation that comprises the protein of the present invention, a modified protein thereof, a homologue of the protein or the modified protein, or a protein produced by the method for producing a protein according to the present invention.

[0046] In general, a cellulase preparation is powder, liquid, or the like that comprises, for example, an excipient (e.g., lactose, sodium chloride, or sorbitol), a preservative, or a nonionic surfactant, in addition to a cellulase enzyme. For example, it is formulated as a powdery, particulate, granular, non-dusting granular, or liquid preparation. The cellulase preparation of the present invention comprises, as the cellulase enzyme, the protein of the present invention, a modified protein thereof, a homologue of the protein or the modified protein, or a protein produced by the method for producing a protein of the present invention (hereinafter referred to as "the proteins of the present invention"). Further, the cellulase preparation of the present invention may comprise, in addition to the proteins of the present invention, other cellulase enzymes, for example, cellobiohydrolase,  $\beta$ -glucosidase, or endoglucanase which are not involved in the present invention.

[0047] One type of cellulase preparation, a non-dusting granular preparation, may be prepared by a conventional dry granulating method. Specifically, the powdery proteins of the present invention are mixed with one or several of: neutral inorganic salts that do not affect endoglucanase activity represented by sodium sulfate, sodium chloride, or the like; minerals that do not affect endoglucanase activity represented by bentonite, montmorillonite, or the like; or neutral organic substances represented by starch, particulate cellulose, or the like. A powder or fine suspension of one or several nonionic surfactant is then added thereto, followed by thorough mixing or kneading. Depending on the situation, a synthetic polymer represented by polyethylene glycol for binding solid matter or a natural polymer such as starch is suitably added and further kneaded. Thereafter, extrusion granulation is carried out using, for example, Disc Pelleter, and the extruded granules are then shaped into spherical form using the Marumerizer, followed by drying. Thus, non-dusting granules can be produced. The amount of one or several nonionic surfactants to be added is not particularly limited. The amount is preferably 0.1% to 50% by weight, more preferably 0.1% to 30% by weight, and still more preferably 1% to 20% by weight, based on the entire cellulase preparation according to the present invention. Oxygen permeation or water permeation can be regulated by coating the surfaces of granules with a polymer, etc.

[0048] In contrast, a liquid formulation can be prepared by incorporating a stabilizer for the endoglucanase enzyme such as a synthetic polymer, a natural polymer, or the like into a solution comprising the proteins of the present invention and adding inorganic salts or synthetic preservatives according to need. In this case, one or several nonionic surfactants can be also incorporated. The amount of one or several nonionic surfactants to be added is not particularly limited. The amount is preferably 0.1% to 50% by weight, more preferably 0.1% to 30% by weight, and still more preferably 1% to 20% by weight, based on the entire cellulase preparation according to the present invention.



## 4. Application of the proteins of the present invention and the cellulase preparation of the present invention

[0049] The present invention relates to a method for treating cellulose-containing fabrics. This method comprises a step of bringing cellulose-containing fabrics into contact with the proteins of the present invention or the cellulase preparation of the present invention. Conditions such as contact temperature or amounts of the proteins or the cellulase preparation can be suitably determined with respect to various other conditions.

[0050] The aforementioned method can be used to reduce the rate at which cellulose-containing fabrics become fuzzy or to reduce fuzzing in cellulose-containing fabrics. In this application, the proteins or the cellulase preparation at the protein concentration of 0.001 to 1 mg/l is preferably used at about 30°C to 60°C.

[0051] The aforementioned method can be used in weight loss treatment of cellulose-containing fabrics to improve the feel and appearance thereof. In this application, to improve the feel means to reduce the rate at which the feel is spoiled. In this application, the proteins or the cellulase preparation at the protein concentration of 0.001 to 100 mg/l is preferably used at about 30°C to 60°C.

[0052] The aforementioned method can be used for color clarification of colored cellulose-containing fabrics.

[0053] The aforementioned method can be used for providing colored cellulose-containing fabrics with partial color change. In this application, for example, colored cellulose-containing fabrics (e.g., denim) can be provided with an appearance of stone-washed material. In this application, the proteins or the cellulase preparation at the protein concentration of 0.01 to 100 mg/l is preferably used at about 40°C to 60°C.

[0054] The protein concentrations of various endoglucanases were calculated from the peak area at UV 280 nm of respective endoglucanase eluted with a linear gradient from 0% to 80% of acetonitrile concentration in 0.05% TFA (trifluoroacetic acid) at a flow rate of 1.0 ml/min in HPLC analysis using TSK gel TMS-250 column (4.6 mm I.D. x 7.5 cm, TOSOH Japan). The standard used was the purified NCE4, which was analyzed in HPLC under the same conditions, the protein concentration of which had been preliminarily measured by a protein assay kit (BioRad Laboratories). The purified NCE4 is purified from a culture product of *Humicola insolens* MN 200-1, which was deposited at the International Patent Organism Depository of the National Institute of Advanced Industrial Science and Technology (Tsukuba Central 6, 1-1-1 Higashi, Tsukuba, Ibaraki, Japan) under the accession number of FERM BP-5977 (initial deposition: FERM P-15736, date of initial deposition: July 15, 1996), in accordance with the method as described in WO 98/03640. The standard used to measure the protein concentration using the protein assay kit is the Albumin Standard (Bovine serum albumin, fraction V, PIERCE).

[0055] The aforementioned method can be used to reduce the rate at which cellulose-containing fabrics become stiff or to reduce stiffness in cellulose-containing fabrics. In this application, cellulose-containing fabrics can be softened.

[0056] In the aforementioned applications, cellulose-containing fabrics can be treated through soaking, washing, or rinsing of the fabrics. Specifically, the aforementioned method of the present invention can be carried out by treating cellulose-containing fabrics during washing. On some occasions, however, the treatment of fabrics may be carried out during soaking or rinsing by adding the proteins or the cellulase preparation of the present invention into water where the fabrics are soaked or to be soaked.

[0057] The present invention relates to an additive to detergent comprising the proteins or the cellulase preparation of the present invention in a non-dusting granular form or a stabilized liquid form. The present invention further relates to a detergent composition comprising the proteins or the cellulase preparation of the present invention.

[0058] This detergent composition may also contain a surfactant (which may be anionic, nonionic, cationic, amphoteric, or zwitterionic surfactant, or a mixture thereof). Further, this detergent composition may contain other detergent components known in the art, such as builders, bleaching agents, bleaching activators, corrosion inhibitors, sequestering agents, soil-dissociating polymers, aromatics, other enzymes (e.g., protease, lipase, or amylase), enzyme stabilizers, formulation assistants, fluorescent brightening agents, foaming promoters, etc. Examples of representative anionic surfactants include linear alkyl benzene sulfonate (LAS), alkylsulfate (AS),  $\alpha$ -olefin sulfonate (AOS), polyoxyethylene alkyl ether sulfate (AES),  $\alpha$ -sulfonato fatty acid methyl ester ( $\alpha$ -SFMe), and alkali metal salts of natural fatty acids. Examples of nonionic surfactants include polyoxyethylene alkyl ether (AE), alkyl polyethylene glycol ether, nonylphenol polyethylene glycol ether, fatty acid methyl ester ethoxylate, fatty acid esters of sucrose or glucose, and esters of alkyl glucoside and polyethoxylated alkylglucoside.

[0059] The use of the proteins or the cellulase preparation of the present invention in a detergent composition can improve performances regarding particulate soil removal, color clarification, fuzz prevention, depilling, and reduction of stiffness.

[0060] The present invention relates to a method of deinking waste paper using a deinking agent wherein the proteins or the cellulase preparation of the present invention is used in a step of deinking waste paper with a deinking agent.

[0061] When the protein or the cellulase preparation of the present invention is acted on waste paper, the efficiency of deinking is enhanced, and thus, the protein or the cellulase preparation of the present invention is useful in the process of manufacturing recycled paper from waste paper. This deinking method can significantly decrease ink-remaining fibers. Therefore, the whiteness of the waste paper can be enhanced.

[0062] The aforementioned "deinking agent" is not particularly limited as long as it is a commonly used agent when deinking waste paper. Examples thereof include alkali such as NaOH or Na<sub>2</sub>CO<sub>3</sub>, sodium silicate, hydrogen peroxide, phosphates, anionic surfactants, nonionic surfactants, capturing agents such as oleic acid, and examples of aids include pH stabilizers, chelating agents, and dispersants.

[0063] Waste paper, which can be treated by the above deinking method, is not particularly limited as long as it can be generally referred to as waste paper. Examples of waste paper include: used printed paper containing mechanical pulp and chemical pulp such as used newspaper, used magazine paper and low-grade or middle-grade used printed paper, used wood-free paper composed of chemical pulp; and coated paper thereof. Further, the above deinking method can be applied to any paper on which ink has been deposited if the paper is not generally referred to as waste paper.

[0064] Further, the present invention relates to a method for improving drainage of paper pulp. This method comprises a step of treating the paper pulp with the proteins or the cellulase preparation of the present invention.

[0065] According to this method, drainage of paper pulp can be remarkably improved without significant deterioration in paper strength. Pulp, which can be treated by this method, is not particularly limited, and examples thereof include waste paper pulp, recycled board pulp, kraft pulp, sulfite pulp, processed or thermo-mechanical pulp, and other high-yield pulp.

[0066] The present invention further relates to a method for improving the digestibility of animal feeds. This method comprises a step of treating animal feeds with the proteins or the cellulase preparation of the present invention.

[0067] According to this method, molecular weights of glucans in animal feeds are suitably lowered. Thus, the digestibility of animal feeds can be improved.

#### 5. Deposition of microorganisms

[0068] The *Rhizopus oryzae* CP96001 strain was deposited at the International Patent Organism Depository of the National Institute of Advanced Industrial Science and Technology (Tsukuba Central 6, 1-1-1 Higashi, Tsukuba, Ibaraki, Japan) under the accession number of FERM BP-6889 on April 21, 1997.

[0069] The *Mucor circinelloides* CP99001 strain was deposited at the International Patent Organism Depository of the National Institute of Advanced Industrial Science and Technology (Tsukuba Central 6, 1-1-1 Higashi, Tsukuba, Ibaraki, Japan) under the accession number of FERM BP-6890 on July 2, 1999.

[0070] The *Phycomyces nitens* CP99002 strain was deposited at the International Patent Organism Depository of the National Institute of Advanced Industrial Science and Technology (Tsukuba Central 6, 1-1-1 Higashi, Tsukuba, Ibaraki, Japan) under the accession number of FERM BP-6891 on July 2, 1999.

[0071] The *Escherichia coli* JM 109 strain that was transformed with the expression vector pMKD01 used in the present invention was deposited at the International Patent Organism Depository of the National Institute of Advanced Industrial Science and Technology (Tsukuba Central 6, 1-1-1 Higashi, Tsukuba, Ibaraki, Japan) under the accession number of FERM BP-5974 (initial deposition: PERM P-15730, date of initial deposition: July 12, 1996).

[0072] The *Humicola insolens* MN 200-1 strain that can be a host for the expression vector of the present invention was deposited at the International Patent Organism Depository of the National Institute of Advanced Industrial Science and Technology (Tsukuba Central 6, 1-1-1 Higashi, Tsukuba, Ibaraki, Japan) under the accession number of FERM BP-5977 (initial deposition: FERM P-15736, date of initial deposition: July 15, 1996).

[0073] This description includes part or all of the contents as disclosed in the description of Japanese Patent Application No. 2000-354296, which is a priority document of the present application.

#### Best Modes for Carrying out the Present Invention

[0074] The present invention is described in more detail with reference to the following examples and reference examples but is not limited thereto.

[0075] In the following description, "endoglucanase activity" refers to CMCase activity. Further, "CMCase activity" measured by the amount of the reducing sugars released after the incubation of a cellulase enzyme and a carboxymethylcellulose (CMC, Tokyo Kasei Kogyo, Japan) solution for a given period of time and one unit is defined as the amount of an enzyme that produces reducing sugars corresponding to 1  $\mu$ mol of glucose per minute.

[0076] In implementing the following tests, examples disclosed in WO 98/03667 and WO 00/24879 were referred to.

## [Reference Examples]

## Reference Example 1: cDNA cloning of cellulase NCE5

## 5 (1) Isolation of cDNA and preparation of library

[0077] In the screening of the gene that encodes NCE5, the cellulase component, mRNA was prepared from *Humicola insolens* MN 200-1 (FERM BP-5977), and cDNA was synthesized by a reverse transcriptase to prepare a library.

## 10 (i) Preparation of total RNA

[0078] *Humicola insolens* MN 200-1 (FERM BP-5977) was cultured in medium (N) (5.0% Avicel, 2.0% yeast extract, 0.1% polypeptone, 0.03% calcium chloride, 0.03% magnesium chloride, pH 6.8) for 2 days, and cells were collected by centrifugation (3,500 rpm, 10 minutes). Among the collected cells, 3 g thereof was washed with sterilized water, frozen in liquid nitrogen, and then ground in liquid nitrogen using a mortar and a pestle. Total RNA was isolated from the ground cells using ISOGEN (Nippon Gene) in accordance with the manual attached thereto, and total RNA was confirmed by formaldehyde agarose gel electrophoresis as a chromatic figure.

## 20 (ii) Preparation of poly(A)tail+RNA (= mRNA)

[0079] Among the total RNA prepared in (i), 1 mg thereof was applied on the oligo (dT) cellulose column to elute and isolate mRNA using the mRNA Purification Kit (Amersham Pharmacia Biotech) in accordance with the attached manual. Further, mRNA was confirmed by formaldehyde agarose gel electrophoresis as a smear chromatic figure.

## 25 (iii) Synthesis of cDNA

[0080] cDNA was synthesized from 5 µg of the mRNA prepared in (ii) using the Time Saver cDNA Synthesis Kit (Amersham Pharmacia Biotech) in accordance with the attached manual.

## 30 (iv) Preparation of cDNA library

[0081] The *Eco*RI-NotI adaptor contained in the Time Saver cDNA Synthesis Kit was ligated to the blunt end of the synthesized total cDNA in accordance with the attached manual. The total amount of this DNA fragment was ligated into the phage vector and the *Eco*RI arm of the λZAPII Cloning Kit (Stratagene) using the DNA Ligation Kit Ver. 2 (Takara Shuzo Co., Ltd.), followed by ethanol precipitation. Thereafter, the DNA fragment was dissolved in a TE (10 mM Tris hydrochloride, pH 8.0, 1 mM EDTA) buffer. The thus obtained recombinant phage vector was subjected to *in vitro* packaging using the Gigapack III Plus Packaging Extract (Stratagene) in accordance with the attached manual. Thereafter, this recombinant phage vector was infected with *Escherichia coli* XL1-Blue MRF' and cultured on a plate for plaque formation. Thus, a phage library was obtained. With the use thereof, an object gene was cloned.

## 40 (2) Amplification and analysis of DNA by PCR

[0082] DNA was amplified by PCR using the cDNA prepared in (i)-(iii) as a template based on the information concerning partial amino acid sequences of the cellulase NCE5.

[0083] The following synthetic oligonucleotides were prepared as primers.  
N-terminal: 5'-TAY TGG GAY TGY TGY AAR CC-3' (20mer) (SEQ ID NO: 36)  
T-43.0: 5'-TCI GCR TTI ARR AAC CAR TC-3' (20mer) (SEQ ID NO: 37)

(In these nucleotide sequences, R indicates G or A; Y indicates T or C; and I indicates inosine.)

[0084] PCR was carried out in 50 µl of reaction solution using 1 µg of cDNA as a template, 1.25 units of LA Taq DNA Polymerase (Takara Shuzo Co., Ltd.) and its attached buffer, 0.2 mM dNTP, 10% DMSO, and 1 µM each of the above primers under the following condition: at 94°C for 1 minute, (at 94.0°C for 30 seconds, 55.0°C for 30 seconds, and 72.0°C for 1 minute) x 25 times, and 72.0°C for 5 minutes.

[0085] About 500 bp DNA was amplified by this reaction, and the amplified DNA was subjected to sequencing using the DYEnamic ET Terminator Cycle Sequencing Premix Kit (Amersham Pharmacia Biotech) and the ABI PRISM 310 Genetic Analyzer (PE Applied Biosystems) in accordance with the attached protocols. As a result, the amino acid sequence, which was deduced from the determined nucleotide sequence, contained all the partial amino acid sequence-

es of cellulase NCE5. Thus, the deduced amino acid sequence was used as a probe in the following screening process.

### (3) Cloning of the gene that encodes NCE5, the cellulase component

#### 5 (i) Screening by plaque hybridization

[0086] The 500 bp DNA fragment (100 ng) amplified by PCR was previously labeled with the ECL Direct DNA/RNA Labeling Detection System (Amersham Pharmacia Biotech).

10 [0087] The phage plaque prepared in (1)-(iv) was transferred to the Hybond-N+ nylon transfer membrane (Amersham Pharmacia Biotech) and subjected to alkali treatment with 0.4N sodium hydroxide. Recombinant phage DNA on the membrane was denatured into a single strand. Thereafter, the nylon membrane was washed with 5x SSC (1x SSC: 15 mM trisodium citrate, 150 mM sodium chloride) and then air dried to immobilize DNA thereon. Thereafter, the nylon membrane was hybridized in accordance with the manual of the kit, detected, and exposed to Fuji Medical X-ray film (Fuji Photo Film) to yield 6 positive clones.

#### 15 (ii) Preparation of phage DNA

[0088] DNA was prepared from the positive clones as plasmid DNA in accordance with the manual attached to the kit.

20 [0089] A plasmid in which a DNA fragment was cloned into pBluescript SK(-) was prepared from ampicillin-resistant *Escherichia coli* SOLR™. Using this plasmid as a template, PCR was carried out using the N-terminal and T-43.0 primers used in (2) under the same conditions as described above. As a result, a 500 bp amplification product was obtained from one plasmid. Thus, it is deduced that the object DNA was cloned into this plasmid. This plasmid was digested with *EcoRI* and then subjected to agarose gel electrophoresis.

25 [0090] As a result, the plasmid was found to contain about 1 kbp *EcoRI* fragment.

#### (4) Determination of cDNA nucleotide sequence

30 [0091] A nucleotide sequence of the about 1 kbp *EcoRI* fragment that was inserted into a positive recombinant pBluescript SK(-) plasmid obtained in (3)-(ii) was determined in the same manner as described above using primers for sequencing T3 and T7. As a result, this nucleotide sequence was found to contain a 672 bp open reading frame (ORF). Amino acid sequences deduced from the nucleotide sequence and the ORF were shown in SEQ ID NO: 39 and SEQ ID NO: 38 in the Sequence Listings.

35 [0092] Further, 1 to 18 amino acid sequences in this ORF were considered to be signal sequences for secreting the protein extracellularly.

#### Reference Example 2: Expression of NCE5 gene in *Humicola insolens*

40 [0093] Plasmid pJD01 (see Example D1 (2) (b) in WO 00/24879) was used as an expression vector in *Humicola insolens* MN 200-1 (PERM BP-5977) and constructed in the following manner.

#### (1) Construction of NCE5 expressing plasmid pJND-c5

##### (i) Site-directed mutagenesis into NCE5 gene

45 [0094] In order to ligate the NCE5 gene to the *Bam*HI site of plasmid pJD01, a primer was constructed so as to previously comprise *Bam*HI site in a sequence immediately upstream of the initiation codon and that immediately downstream of the termination codon, and the NCE5 gene was amplified by PCR. Primers for mutagenesis were designed as shown below.

NCE5-N-*Bam*HI:

50

5'-GGGGATCCTGGGACAAGATGCAGCTCCCCCTGACCACG-3' (38mer) (SEQ ID NO: 40);

55 NCE5-C-*Bam*HI:

5'-GGGGATCCTGCATTAAACGCGAGCAGCCGCTCTTGCC-3' (38mer) (SEQ ID NO: 41).

[0095] PCR was carried out under the same conditions as described above using the positive recombinant pBlue-script SK(-) plasmid obtained in Reference Example 1 as a template. As a result, an about 670 bp amplification product of the DNA fragment was confirmed by 1.0% agarose gel electrophoresis. Unreacted matter was removed by the MicroSpin S-400 HR Columns (Amersham Pharmacia Biotech), precipitated with ethanol, and then digested with *Bam*-HI. Subsequently, a total amount was subjected to 1.0% agarose gel electrophoresis, a 670 bp DNA fragment was collected using the Sephaglas BandPrep Kit (Amersham Pharmacia Biotech) in accordance with the attached manual, and the *Bam*HI fragment was subcloned into the *Bam*HI site of plasmid pUC118 to yield plasmid pNCE5Bam. Further, the nucleotide sequence of this inserted fragment was determined and confirmed by the aforementioned method.

(ii) Preparation of plasmid pJND-c5

[0096] The above plasmid pJD01 was digested with *Bam*HI and separated by 0.8% agarose gel electrophoresis. An about 8.0 kbp DNA fragment was collected by the Sephaglas BandPrep Kit, and the collected DNA fragment was dephosphorylated using *Escherichia coli*-derived alkaline phosphatase (Takara Shuzo Co., Ltd.) in accordance with the attached manual. Similarly, the plasmid pNCE5Bam obtained in (i) was digested with *Bam*HI, and 670 bp DNA fragments were collected and ligated to the above DNA fragment using the DNA Ligation Kit Ver. 2 to obtain expression plasmid pJND-c5.

(2) Transformation of *Humicola insolens* with plasmid pJND-c5

[0097] *Humicola insolens* MN 200-1 (FERM BP-5977) was cultured in medium (S) at 37°C for 24 hours, and then the cells were collected by centrifugation at 3,000 rpm for 10 minutes. Medium (S) is composed of medium (N) described in Reference Example 1 having glucose (3.0%) added thereto and Avicel removed therefrom. The collected cells were washed with 0.5M sucrose and suspended in 10 ml of enzyme solution for preparing protoplast (3 mg/ml  $\beta$ -glucuronidase, 1 mg/ml Chitinase, 1 mg/ml Zymolyase, and 0.5M sucrose) filtered through a 0.45  $\mu$ m filter. The suspension was shaken at 30°C for 60 to 90 minutes to render fungal threads to be protoplasted. This suspension was filtered and then centrifuged at 2,500 rpm for 10 minutes, and the protoplast was collected and then washed with a SUTC buffer (0.5M sucrose, 10 mM calcium chloride, and 10 mM Tris hydrochloride (pH 7.5)).

[0098] The thus prepared protoplast was suspended in 1 mL of SUTC buffer, and 10  $\mu$ l of DNA (TE) solution was added to the suspension in amounts of 10  $\mu$ g per each 100  $\mu$ l of the suspension. The mixture was allowed to stand in ice for 5 minutes. Subsequently, 400  $\mu$ l of PEG solution (60% PEG 4000, 10 mM calcium chloride, 10 mM Tris hydrochloride (pH 7.5)) was added and the mixture was allowed to stand in ice for 20 minutes. Thereafter, 10 ml of SUTC buffer was added, and centrifugation was carried out at 2,500 rpm for 10 minutes. The collected protoplast was suspended in 1 ml of SUTC buffer, centrifuged at 4,000 rpm for 5 minutes, and finally suspended in 100  $\mu$ l of SUTC buffer.

[0099] The protoplast treated as above was superposed on the hygromycin-added (200  $\mu$ g/ml) YMG medium (1% glucose, 0.4% yeast extract, 0.2% malt extract, 1% agar (pH 6.8)) together with YMG soft agar. Culture was incubated at 37°C for 5 days. Thereafter, the generated colony was determined to be a transformant.

[Example 1] Construction of gene expressing RCE I variant H43, which lacks the cellulose-binding domain

[0100] Plasmid p18-1 containing the codon optimized endoglucanase gene RCE I (see Example D3 (1) g) in WO 00/24879) was digested with the restriction enzyme *Bam*HI to prepare plasmid pR1H4 wherein a fragment containing the codon optimized endoglucanase gene has been cloned into the *Bam*HI site of plasmid pUC118. This plasmid pR1H4 was used as a template to perform first-phase PCR using two synthetic DNAs, i.e., RC-43F and RC-43R, as primers and the TaKaRa LA PCR in vitro Mutagenesis Kit (Takara Shuzo Co., Ltd.). Reaction conditions were in accordance with the manual attached to the kit. A sample was separated after the reaction by agarose gel electrophoresis to obtain an about 650 bp gene fragment 43-X2.

[0101] Using plasmid pJND-c5 as a template, which comprises the NCE5 gene originally having no cellulose-binding domain and being a family 45 endoglucanase as described in Reference Example 2, first-phase PCR was similarly carried out using two synthetic DNAs, i.e., NX-43F and NX-43R, as primers and the TaKaRa LA PCR in vitro Mutagenesis Kit (Takara Shuzo Co., Ltd.). Reaction conditions were in accordance with the manual attached to the kit. A sample was separated after the reaction by agarose gel electrophoresis to obtain an about 120 bp gene fragment 43-X1.

RC-43F: CACCACGCGCTACTGGGACT (SEQ ID NO: 20);

RC-43R: GGATCCTGCGTTTACTTGC (SEQ ID NO: 21);

NX-43F: GGATCCTGGGACAAGATG (SEQ ID NO: 22);

NX-43R: GCACGACGGCTTGCAGC (SEQ ID NO: 23)

[0102] Annealing and second-phase PCR were carried out using PCR fragments 43-X1 and 43-X2 and the TaKaRa LA PCR in vitro Mutagenesis Kit. Two synthetic DNAs, i.e., NX-43F and RC-43R, were used as primers and reaction conditions were in accordance with the manual attached to the kit. A sample was separated after the reaction by agarose gel electrophoresis to obtain an about 700 bp gene fragment H43. This fragment was digested with the restriction enzyme *Bam*HI to prepare plasmid pR1H43 ligated to the *Bam*HI site of plasmid pUC118 using the TaKaRa DNA Ligation Kit Ver. 1. Reaction conditions, such as those regarding enzymes, were in accordance with the manual attached to the kit. The obtained plasmid pR1H43 was subjected to sequencing using the Cy5-Auto Read Sequencing Kit (Amersham Pharmacia), and the sequence was analyzed using the DNA Sequencer ALFred (Amersham Pharmacia). A primer used in the reaction was the M13 primer, which was attached to the kit. As a result, it was confirmed that the sequence was in the expected form, i.e., a secretion signal on the N-terminal side was derived from NCE5 and the remaining catalytic active domain (CAD) was a sequence derived from RCE I. The amino acid sequence of the RCE I variant H43 deduced from the nucleotide sequence is shown below.

H43: MQLPLTLLTLLPALAAQSGSGRTRYWDCCKPSCSWPGKANVSSPVKSCNKDG  
VTALSDSNAQSGCNGGNSYMCNDNQPWAVNDNLAYGFAAAISGGGESRWCCSCFELTF  
TSTSVAGKKMVVQVTINTGGDLGSSTGAHFDLQMPGGGVGIFNGCSSQWGAPNDGWGSR  
YGGISSASDCSSLPALQAGCKWRFNWFKNADNPSTYKEVTCPEITAKTGCSRK  
(SEQ ID NO: 24)

[0103] In this amino acid sequence (SEQ ID NO: 24), amino acid residues 1 to 18 are signal peptides derived from NCE5, amino acid residues 19 to 24 are N-terminal sequences of LACE5, amino acid residues 25 to 36 are sequences derived from NCE5 or RCE I, and amino acid residue 37 and succeeding sequences are derived from the catalytic active domain of RCE I.

[0104] When the reaction is carried out in accordance with the above method, two types of sequences, i.e., the sequence as shown in SEQ ID NO: 24 and the sequence in which amino acid residue 34 is alanine, are obtained as amino acid sequences of the protein coded by the nucleotide sequence of the gene fragment H43. In the following procedure, a gene fragment used has a nucleotide sequence, which encodes the amino acid sequence as shown in SEQ ID NO: 24.

[Example 2] Construction of gene expressing RCE I variant H45 which lacks the cellulose-binding domain

[0105] pR1H4 obtained in Example 1 was used as a template to introduce amino acid substitution into the RCE I gene using synthetic DNA, RC-A121P, and the TaKaRa LA PCR in vitro Mutagenesis Kit (Takara Shuzo Co., Ltd.). Reaction conditions were in accordance with the manual attached to the kit. A sample was separated after the reaction by agarose gel electrophoresis to obtain an about 1-kbp gene fragment L9. This fragment was digested with the restriction enzyme *Bam*HI and ligated to the *Bam*HI site of plasmid pUC118 using the TaKaRa DNA Ligation Kit Ver. 1 to prepare plasmid pR1L9. Reaction conditions, such as those regarding enzymes, were in accordance with the manual attached to the kit. The obtained plasmid pR1L9 was subjected to sequencing reaction using the Cy5-Auto Read Sequencing Kit (Amersham Pharmacia), and the sequence was analyzed using the DNA Sequencer ALFred (Amersham Pharmacia). A synthetic DNA used as primer used in this reaction was H4-R1. As a result, it was confirmed that the sequence was in the expected form, i.e., one alanine was substituted with proline.

RC-A121P: GACTGCTGCAAGCCGTCGTGC (SEQ ID NO: 42);

5

H4-R1: GTTGCACATGTAGGAGTTGC (SEQ ID NO: 43)

[0106] Using this pR1L9 as a template, a gene encoding a portion of the secretion signal sequence in the RCE I gene was amplified. PCR was carried out using two synthetic DNAs, i.e., RC-451F and RC-451R, as primers, the TaKaRa Ex Taq Polymerase (Takara Shuzo Co., Ltd.), and attached buffers. The composition of the reaction solution was in accordance with the conditions specified in the attached manual. The temperature conditions for the Thermal Cycler (2400-R; Perkin Elmer) were 25 cycles of 94°C for 1 minute, 50°C for 2 minutes, and 72°C for 1 minute. A sample was separated after the reaction by agarose gel electrophoresis to obtain an about 100 bp gene fragment 45-X1.

[0107] Similarly, a region encoding the catalytic active domain (CAD) of the RCE I gene was amplified using the pR1L9 as a template. PCR was carried out using two synthetic DNAs, i.e., RC-452F and RC-452R, as primers, the TaKaRa Ex Taq Polymerase (Takara Shuzo Co., Ltd.), and attached buffers. The composition of the reaction solution was in accordance with the conditions specified in the attached manual. The temperature conditions for the Thermal Cycler (2400-R; Perkin Elmer) were 25 cycles of 94°C for 1 minute, 50°C for 2 minutes, and 72°C for 1 minute. A sample was separated after the reaction by agarose gel electrophoresis to obtain an about 630 bp gene fragment 45-X2.

20

RC-451F: GCGGATCCTGGGACAAGATG (SEQ ID NO: 25);

25

RC-451R: GCCTGCAGAGCGGCGGAGGCCATC (SEQ ID NO: 26);

RC-452F: GCCTGCAGGGAAAGTACAGCGCTGT (SEQ ID NO: 27);

30

RC-452R: GCGGATCCTGCGTTTACTTGC (SEQ ID NO: 28)

[0108] PCR fragments 45-X1 and 45-X2 were digested with the restriction enzyme *Pst*I, ligated together using the TaKaRa DNA Ligation Kit Ver. 1, and then digested with the restriction enzyme *Bam*HI to obtain a DNA fragment 45-X3. PCR was carried out using 45-X3 as a template, two synthetic DNAs, i.e., RC-451F and RC-452R, as primers, the TaKaRa Ex Taq Polymerase (Takara Shuzo Co., Ltd.), and attached buffers. The composition of the reaction solution was in accordance with the conditions specified in the attached manual. The temperature conditions for the Thermal Cycler (2400-R; Perkin Elmer) were 25 cycles of 94°C for 1 minute, 50°C for 2 minutes, and 72°C for 1 minute. A sample was separated after the reaction by agarose gel electrophoresis to obtain an about 700 bp gene fragment H45. This fragment was digested with the restriction enzyme *Bam*HI and ligated to the *Bam*HI site of plasmid pUC118 using the TaKaRa DNA Ligation Kit Ver. 1 to prepare plasmid pR1H45. Reaction conditions were in accordance with the manual attached to the kit. The amino acid sequence of the RCE I variant H45 deduced from the nucleotide sequence is shown below.

45

H45: MKFTTIASSALLALALGTEMASAALQGKYSVSGGASGNGVTTRYWDCKPSCSW

50

PGKANVSSPVKSCNKDGVLTALSDSNAQSGCNGGNSYMCNDNQPWAVNDNLAYGFAAA

AISGGGESRWCCSCFELTFTSTSVAGKKMVVQVTNTGGDLGSSTGAHFDLQMPGGGVGIF

55

NGCSSQWGAPNDGWGSGRYGGISSASDCSSLPSALQAGCKWRFFNWFKNADNPSMTYKEV  
TCPKEITAKTGCSRK (SEQ ID NO: 29)

[0109] In this amino acid sequence (SEQ ID NO: 29), amino acid residues 1 to 23 are signal peptides derived from

RCE1, amino acid residue 24 is an N-terminal sequence of RCE I, amino acid residues 25 and 26 are sequences introduced by a primer used, and amino acid residue 27 and succeeding sequences are derived from the catalytic active domain of RCE I.

- 5 [Example 3] Expression of codon optimized endoglucanase RCE I gene and its variants RCE I-H43 and H45, which lack the celluloses-binding domains, in *Humicola insolens*

[0110] Plasmid pJD01 (see Example D1 (2) (b) in WO 00/24879) was digested with BamHI and dephosphorylated using *Escherichia coli*-derived alkaline phosphatase (Takara Shuzo Co., Ltd.) in accordance with the attached manual. Plasmids pR1H43 and pR1H45 obtained in Examples 1 and 2 respectively were also digested with BamHI to produce about 700 bp DNA fragments. The obtained fragments were ligated respectively with aforementioned plasmid pJD01 using the DNA Ligation Kit Ver. 1 to produce expression plasmids pJND-H43 and pJND-H45.

[0111] *Humicola insolens* MN 200-1 (FERM BP-5977) was transformed with pJND-H43, pJND-H45, or pJ14D01 comprising the codon optimized RCE I gene (plasmid comprising a codon optimized RCE I gene to express the Rhizopus-derived RCE I in *Humicola*, see Example D3 (3) in WO 00/24879). Specifically, *Humicola insolens* MN 200-1 (FERM BP-5977) was cultured in medium (S) (3.0% glucose, 2.0% yeast extract, 0.1% polypeptone, 0.03% calcium chloride, 0.03% magnesium chloride (pH 6.8)) at 37°C for 24 hours, and then the cells were collected by centrifugation at 3,000 rpm for 10 minutes. The collected cells were washed with 0.5M sucrose and suspended in 10 ml of enzyme solution for preparing protoplast (5 mg/ml Novozyme 234 (Novo), 5 mg/ml Cellulase Onozuka R-10 (Yakult), and 0.5M sucrose) filtered through a 0.45 µm filter. The suspension was shaken at 30°C for 60 to 90 minutes to render fungal threads to be protoplasted. This suspension was filtered and then centrifuged at 2,500 rpm for 10 minutes, and protoplast was collected and washed with a SUTC buffer (0.5M sucrose, 10 mM calcium chloride, and 10 mM Tris hydrochloride (pH 7.5)).

[0112] The thus prepared protoplast was suspended in 1 mL of SUTC buffer, and 10 µl of DNA (TE) solution was added to the suspension in amounts of 10 µg per each 100 µl of the suspension. The mixture was allowed to stand in ice for 5 minutes. Subsequently, 400 µl of PEG solution (60% PEG 4000, 10 mM calcium chloride, and 10 mM Tris hydrochloride (pH 7.5)) was added and the mixture was allowed to stand in ice for 20 minutes. Thereafter, 10 ml of SUTC buffer was added, and centrifugation was carried out at 2,500 rpm for 10 minutes. The collected protoplast was suspended in 1 ml of SUTC buffer, centrifuged at 4,000 rpm for 5 minutes, and finally suspended in 100 µl of SUTC buffer.

[0113] The protoplast treated as above was superposed on a 200 µg/ml hygromycin B-containing YMG medium (1% glucose, 0.4% yeast extract, 0.2% malt extract, 1% agar (pH 6.8)) together with YMG soft agar. Culture was incubated at 37°C for 5 days. Thereafter, the generated colony was determined to be a transformant.

[0114] The obtained transformant was cultured in medium (N) (5.0% Avicel, 2.0% yeast extract, 0.1% polypeptone, 0.03% calcium chloride, 0.03% magnesium chloride, pH 6.8) at 37°C. A culture supernatant from which solid matter has been removed by centrifugation was determined to be an enzyme sample.

[Example 4] Isolation and purification of RCE I variant from *Humicola insolens* transformant

[0115] *Humicola insolens* transformants were inoculated to medium (N) (5.0% Avicel, 2.0% yeast extract, 0.1% polypeptone, 0.03% calcium chloride, 0.03% magnesium chloride, (pH 6.8)) and subjected to shake culture at 37°C. Transformants into which plasmids pJND-H43 and pJND-H45 had been introduced were cultured for 5 to 6 days. Regarding transformants into which plasmid pJ14D01 had been introduced, a sample was cultured for 4 days for obtaining an RCE I enzyme, which was not degraded in its linker domain, and which sustained a cellulose-binding domain. In contrast, a sample was cultured longer than 4 days, i.e., for 5 to 6 days, for obtaining the RCE I enzyme, which was degraded in its linker domain and lacked the cellulose-binding domain. Each of the resulting culture solutions was centrifuged at 7,000 rpm for 20 minutes to remove cells, and the culture supernatant was determined to be a crude cellulase preparation.

[0116] An ammonium sulfate solution at a final concentration of 1.5 M was prepared from 100 ml of this crude cellulase preparation and then applied at a flow rate of 10.0 ml/min to Macro-Prep Methyl HIC Support hydrophobic chromatography (270 ml in gel volume, BioRad Laboratories) which had been previously equilibrated with 1.5 M ammonium sulfate solution. It was then fractionated by eluting at a flow rate of 10.0 ml/min in a stepwise elution method in which the concentration of ammonium sulfate was decreased by 0.3 M each from 1.5 M. Fractions found to have strong activity of removing fuzz from lyocell were: a fraction obtained at an ammonium sulfate concentration of 1.2 M regarding a culture solution of the transformant into which plasmid pJND-H43 had been introduced (hereinafter referred to as an "H43 culture solution"); a fraction obtained at an ammonium sulfate concentration of 0.9 M regarding a culture solution of the transformant into which plasmid pJND-H45 had been introduced (hereinafter referred to as an "H45 culture solution"); a fraction obtained at an ammonium sulfate concentration of 0.6 M regarding a culture solution of the trans-



formant into which plasmid pJ14D01 had been introduced and cultured for 4 days (hereinafter referred to as an "H4 culture solution"); and a fraction obtained at an ammonium sulfate concentration of 0.9 M regarding a culture solution of the transformant into which plasmid pJ14D01 had been introduced and for which a culture period had been extended to accelerate its degradation (hereinafter referred to as an "H4 degradation product"). Therefore, 100 ml each of these fractions was fractionated.

[0117] An ammonium sulfate solution at a final concentration of 1.5 M was prepared from 100 ml of the obtained active fractions and then applied again at a flow rate of 10.0 ml/min to Macro-Prep Methyl HIC Support hydrophobic chromatography (270 ml in gel volume, BioRad Laboratories) which had been previously equilibrated with 1.5 M ammonium sulfate solution. It was then fractionated by eluting at a flow rate of 10.0 ml/min in a stepwise elution method in which the concentration of ammonium sulfate in deionized water was decreased by 0.15 M each from 1.5 M. Fractions found to have activities of removing fuzz from lycell were: a fraction obtained at an ammonium sulfate concentration of 1.35 M regarding the H43 culture solution; a fraction obtained at an ammonium sulfate concentration of 1.05 M regarding the H45 culture solution; a fraction obtained at an ammonium sulfate concentration of 0.75 M regarding the H4 culture solution; and a fraction obtained at an ammonium sulfate concentration of 1.05 M regarding the H4 degradation product. Therefore, 40 ml each of these fractions was fractionated.

[0118] An ammonium sulfate solution at a final concentration of 1.5 M was prepared from 40 ml of the obtained active fractions and then applied at a flow rate of 4.0 ml/min to Macro-Prep Methyl HIC Support hydrophobic chromatography (25 ml in gel volume, BioRad Laboratories) which had been previously equilibrated with 1.5 M ammonium sulfate solution. It was then fractionated by eluting at a flow rate of 4.0 ml/min in deionized water. Among these fractions, 8 ml of fraction, which was found to have strong activity of removing fuzz from lycell, was fractionated.

[0119] Acetate buffer (150 ml, 50 mM, pH 4.0) was prepared by diluting the obtained active fractions, and the resulting buffer was then applied at a flow rate of 2 ml/min to MonoS 10-/10-HR column (Amersham Pharmacia), which had been previously equilibrated with 50 mM acetate buffer (pH 4.0). It was then fractionated by eluting at a flow rate of 2 ml/min in a stepwise elution method in which the concentration of NaCl in 50 mM acetate buffer (pH 4.0) was increased by 0.1 M each to 1M NaCl in 50 mM acetate buffer (pH 5.0). Fractions that were obtained at a NaCl concentration of about 0.2 to 0.3M were found to have activity of removing fuzz from lycell. Therefore, 6 ml of fraction found to have the strongest activity was fractionated. These fractions showed in SDS-PAGE a single band of about 25 KDa regarding proteins purified from the H43 culture solution, the H45 culture solution, and the H4 degradation product and a single band of about 40 KDa regarding the protein purified from the H4 culture solution.

[0120] SDS-PAGE was carried out using the system of Tefco in which an electrophoresis tank (No. 03-101), a source (Model: 3540), 10% gel (01-015), and a buffer kit for SDS-PAGE (06-0301) were used. The condition for electrophoresis was 18 mA/10 min and then 20 mA/90 min. In protein detection after the electrophoresis, silver staining was carried out using a 2D-silver staining reagent IT "DAIICHI" (Daiichi Pure Chemicals Co., Ltd.) for electrophoresis. A standard protein used as a marker was the SDS-PAGE molecular weight standard protein, Low Range (161-0304, BioRad).

[0121] The activity of removing fuzz from lycell was measured in accordance with the following method.

[0122] Color knitted fabric of lycell (Toyoshima Japan) was fuzzed in a large washer together with a surfactant and rubber balls. Thereafter, the fuzzy knitted fabric of lycell (Toyoshima Japan, 9 cm x 10 cm, about 2 g in weight) was cylindrically sewn and subjected to fuzz removal treatment with various enzymes under the conditions as set forth below. The protein concentrations required to completely remove fuzz existing in the cylindrical fabric by this treatment were calculated.

[0123] The protein concentrations of various endoglucanases were calculated from the peak area at UV 280 nm of respective endoglucanase eluted with a linear gradient from 0% to 80% of acetonitrile concentration in 0.05% TFA (trifluoroacetic acid) at a flow rate of 1.0 ml/min in HPLC analysis using TSK gel TMS-250 column (4.6 mm LD. x 7.5 cm, TOSOH Japan). The standard used was the purified NCE4, which was analyzed in HPLC under the same conditions, the protein concentration of which had been preliminarily measured by the protein assay kit (BioRad Laboratories). The standard used to measure the protein concentration for the protein assay kit was albumin standard (Bovine serum albumin, fraction V, PIERCE). The purified NCE4 (coded by nucleotides 118 to 1088 in SEQ ID NO: 18) was isolated and purified from a culture solution of *Humicola insolens* according to the method described in WO 98/03640.

Test machine: Launder Meter L-12 (Daiei Kagaku Seiki MFG, Japan)

Temperature: 55°C

Time: 60 minutes

Reaction volume: 40 ml

Reaction pH: pH 5 (10 mM acetate buffer)

pH 6 (10 mM acetate buffer)

[0124] The treating liquid contained 4 rubber balls (about 16 g each) together with the endoglucanase solution.

[Example 5] Identification of N-terminal amino acid sequences of RCE I variant protein isolated and purified from *Humicola insolens* transformant

[0125] In order to determine the N-terminal amino acid sequences of the purified proteins obtained in Example 4, each of the fractions was subjected to SDS-PAGEmini (Tefco), electroblotted on a PVDF membrane, stained with Coomassie Brilliant Blue R-250 (Nacalai Tesque, Inc.), decolorized, washed with water, and then air dried. A portion on which the object protein had been blotted was cleaved out therefrom and subjected to a Protein Sequencer (Model 492, PE Applied Biosystems) to analyze the N-terminal amino acid sequence. The amino acid sequences were read from enzymes that were purified from the H45 culture solution, the H4 culture solution, and the H4 degradation product without any problem. Regarding the enzyme purified from the H43 culture solution, however, no signal was generated by Edman degradation and the N-terminal amino acid was found to be modified and protected. Thus, this enzyme was immersed in a solution of 0.5% polyvinyl pyrrolidone (molecular weight: 40,000, Sigma)/100 mM acetic acid at 37°C for 30 minutes, and, after a protein unbound portion on the membrane was blocked, this enzyme was treated with pfu Pyroglutamate Aminopeptidase (Takara Shuzo Co., Ltd.) at 50°C for 5 hours to remove the modified N-terminal residue. Thus, sequencing was carried out once more. The obtained sequences were as shown below.

The N-terminal amino acid sequence of RCE I-H43:

[0126]

**Gln-Ser-Gly-Ser-Gly-Arg-Thr (7 residues) (SEQ ID NO: 30).**

The N-terminal amino acid sequence of RCE I-H45:

[0127]

**Lys-Tyr-Ser-Ala-Val-Ser-Gly (7 residues) (SEQ ID NO: 31);**

and

**Ala-Val-Ser-Gly-Gly-Ala-Ser (7 residues) (SEQ ID NO: 32).**

The N-terminal amino acid sequence of RCE I-H4(25KDa):

[0128]

**Ser-Ala-Val-Ser-Gly-Gly-Ala (7 residues) (SEQ ID NO: 33);**

and

**Gly-Gly-Ala-Ser-Gly-Asn-Gly (7 residues) (SEQ ID NO: 34).**

The N-terminal amino acid sequence of RCE I-H4 (40KDa):

[0129]

**Ala-Glu-(Cys)-Ser-Lys-Leu-Tyr (7 residues) (SEQ ID NO: 35).**

[0130] As a result of identification of N-terminal amino acid sequences, it was found that only the enzyme purified from the H4 culture solution (hereinafter referred to as "RCE I-H4 (40 KDa)") had a cellulose-binding domain (CBD) while any of the remaining enzyme purified from the H43 culture solution (hereinafter referred to as "RCE I-H43 (25 KDa)"), the enzyme purified from the H45 culture solution (hereinafter referred to as "RCE I-H45 (25 KDa)"), or the enzyme purified from the H4 degradation product (hereinafter referred to as "RCE I-H4 (25 KDa)") had no cellulose-binding domain (CBD) but had only the catalytic active domains (CAD).

[Example 6] Comparison of specific activity of removing fuzz from cotton fabric between RCE I, which lacks the cellulose-binding domain, and RCE L which has the cellulose-binding domain

[0131] Using the endoglucanase which was homogenously purified in Example 5, a knitted cotton fabric (a 6 cm x 8 cm fabric from cotton smooth knit No. 3900, Nitto Boseki Co., Ltd., dyed in brown by reactive dye at Tsuyatomo Senko), which has been fuzzed in a large washer, was subjected to fuzz removal under the following conditions. The amount of fuzz remaining unremoved was visually evaluated, and the amount of purified enzyme to be added so that the amount of remaining fuzz would reach 50% was determined. The amount of protein was determined using the BCA Protein Assay Reagent (PIERCE) in accordance with the conditions described in the attached manual. The estimated molecular weight of the 40 KDa purified RCE I protein (RCE I-H4 (40 KDa)) is about 1.5 times higher than those of the 25 KDa purified RCE I proteins (RCE I-H43 (25 KDa)), RCE I-H45 (25 KDa)), and RCE I-H4 (25 KDa)). Accordingly, even though the quantified amounts of proteins are the same, the number of enzyme molecules in the 40 KDa purified RCE I protein is only about two-thirds of that in the 25 KDa purified RCE I protein in terms of the number of enzyme molecules contained in the protein.

Test machine: Launder Meter L-20 (Daiei Kagaku Seiki MFG, Japan)

Temperature: 40°C or 55°C

Time: 120 minutes

Reaction volume: 40 ml

Reaction pH: Reacted at pH 7 (1 mM phosphate buffer, prepared using deionized water).

[0132] The treating liquid contained 4 rubber balls (about 16 g each) together with the enzyme solution.

[0133] The results are as shown in Table 2 below.

Table 2

	The amount of enzyme added 40°C	The amount of enzyme added 55°C
Purified RCE I-H4 (40 KDa)	390 µg or more	390 µg or more
Purified RCE I-H4 (25 KDa)	18 µg	53 µg

[0134] As is apparent from the results shown in Table 2, the 25 KDa protein, which lacks the cellulose-binding domain (CBD), exhibits much higher activity of removing fuzz from cotton fabrics than the 40 KDa protein, which has the cellulose-binding domain (CBD), even though both proteins are originated from the same *Zygomycetes*-derived endoglucanases RCE I.

[Example 7] Comparison of specific activity of removing fuzz from lyocell fabric between RCE I, which lacks the cellulose-binding domain, and RCE L, which has the cellulose-binding domain

[0135] Using the endoglucanase which was homogenously purified in Example 5, a lyocell fabric (6 cm x 8 cm, Toyoshima Japan) was subjected to fuzz removal under conditions improved from the method described in Example 4. The amount of fuzz remaining unremoved was visually evaluated, and the amount of purified enzyme required to completely remove fuzz was determined. The amount of protein was determined using the BCA Protein Assay Reagent (PIERCE) in accordance with the conditions described in the attached manual. The estimated molecular weight of the 40 KDa purified RCE I protein (RCE I-H4 (40 KDa)) is about 1.5 times higher than those of the 25 KDa purified RCE I proteins (RCE I-H43 (25 KDa)), RCE I-H45 (25 KDa)), and RCE I-H4 (25 KDa)). Accordingly, even though the quantified amounts of proteins are the same, the number of enzyme molecules in the 40 KDa purified RCE I protein is only about two-thirds of that in the 25 KDa purified RCE I protein in terms of the number of enzyme molecules contained in the protein. Test machine: Launder Meter L-20 (Daiei Kagaku Seiki MFG, Japan)

Temperature: 40°C

Time: 90 minutes

Reaction volume: 50 ml

Reaction pH: Reacted at pH 6 (10 mM acetate buffer, prepared using deionized water).

[0136] The treating liquid contained 4 rubber balls (about 16 g each) together with the enzyme solution.

[0137] The results are as shown in Table 3 below.

Table 3

	The amount of enzyme added
Purified RCE I-H4 (40 KDa)	32 µg
Purified RCE I-H4 (25 KDa)	11 µg

[0138] As is apparent from the results shown in Table 3, RCE I, which is Zygomycetes-derived endoglucanase, exhibits a higher specific activity of removing fuzz from lyocell fabrics as the 25 KDa protein, which lacks the cellulose-binding domain (CBD), than as the 40 KDa protein, which has the cellulose-binding domain (CBD).

[Example 8] Comparison of specific activity of removing fuzz from cotton fabric between RCE I, which lacks the cellulose-binding domain, and RCE I, which has the cellulose-binding domain, under alkaline, low-temperature, and surfactant-present conditions

[0139] Using the endoglucanase which was homogenously purified in Example 5, a knitted cotton fabric (a 6 cm x 8 cm fabric from cotton smooth knit No. 3900, Nitto Boseki Co., Ltd., dyed in brown by reactive dye at Tsuyatomo Senko), which had been fuzzed in a large washer, was subjected to fuzz removal under the following conditions. The amount of fuzz remaining unremoved was visually evaluated, and the amount of purified enzyme to be added so that the amount of remaining fuzz would reach 50% was determined. The amount of protein was determined using the BCA Protein Assay Reagent (PIERCE) in accordance with the conditions described in the attached manual. The estimated molecular weight of the 40 KDa purified RCE I protein (RCE I-H4 (40 KDa)) is about 1.5 times higher than those of the 25 KDa purified RCE I proteins (RCE I-H43 (25 KDa)), RCE I-H45 (25 KDa)), and RCE I-H4 (25 KDa)). Accordingly, even though the quantified amounts of proteins are the same, the number of enzyme molecules in the 40 KDa purified RCE I protein is only about two-thirds of that in the 25 KDa purified RCE I protein in terms of the number of enzyme molecules contained in the protein.

Test machine: Launder Meter L-20 (Daiei Kagaku Seiki MFG, Japan)

Temperature: 30°C

Time: 120 minutes

Reaction volume: 40 ml

Reaction pH: Reacted at pH 10 (5 mM sodium carbonate buffer, prepared using deionized water).

[0140] The treating liquid contained a nonionic surfactant Persoft NK-100 (NOF Corp.) at a final concentration of 100 ppm together with the enzyme solution and 4 rubber balls (about 16 g each).

[0141] The results are as shown in Table 4 below.

Table 4

	The amount of enzyme added
Purified RCE I-H4 (40 KDa)	390 µg or more
Purified RCE I-H4 (25 KDa)	52 µg

[0142] As is apparent from the results shown in Table 4, given the low-temperature, alkaline, and surfactant-present conditions under which detergents are actually used, the 25 KDa protein, which lacks the cellulose-binding domain (CBD), exhibits much higher activity of removing fuzz from cotton fabrics than the 40 KDa protein, which has the cellulose-binding domain (CBD), even though both proteins are originated from the same Zygomycetes-derived endoglucanases RCE I.

[Example 9] Comparison of specific activity of removing fuzz from cotton fabric among various purified RCE I proteins, which lack the cellulose-binding domains

[0143] Using the endoglucanase which was homogenously purified in Example 5, a knitted cotton fabric (a 6 cm x 8 cm fabric from cotton smooth knit No. 3900, Nitto Boseki Co., Ltd., dyed in brown by reactive dye at Tsuyatomo Senko), which had been fuzzed in a large washer, was subjected to fuzz removal under the following conditions. The amount of fuzz remaining unremoved was visually evaluated, and the amount of purified enzyme to be added so that the amount of remaining fuzz would reach 50% was determined. The amount of protein was determined using the BCA Protein Assay Reagent (PIERCE) in accordance with the conditions described in the attached manual. The estimated

molecular weight of the 40 KDa purified RCE I protein (RCE I-H4 (40 KDa)) is about 1.5 times higher than those of the 25 KDa purified RCE I proteins (RCE I-H43 (25 KDa)), RCE I-H45 (25 KDa)), and RCE I-H4 (25 KDa)). Accordingly, even though the quantified amounts of proteins are the same, the number of enzyme molecules in the 40 KDa purified RCE I protein is only about two-thirds of that in the 25 KDa purified RCE I protein in terms of the number of enzyme molecules contained in the protein.

Test machine: Launch Meter L-20 (Daiei Kagaku Seiki MFG, Japan)

Temperature: 40°C

Time: 120 minutes

Reaction volume: 40 ml

Reaction pH: Reacted at pH 7 (1 mM phosphate buffer, prepared using deionized water).

[0144] The treating liquid contained 4 rubber balls (about 16 g each) together with the enzyme solution.

[0145] The results are as shown in Table 5 below.

Table 5

	The amount of enzyme added
Purified RCE I-H4 (40 KDa)	390 µg or more
Purified RCE I-H43 (25 KDa)	26 µg
Purified RCE I-H45 (25 KDa)	18 µg
Purified RCE I-H4 (25 KDa)	18 µg

[0146] As is apparent from the results shown in Table 5, various RCE I proteins such as RCE I-H43 (25 KDa), RCE I-H-45 (25 KDa), and RCE I-H4 (25 KDa), which lack the cellulose-binding domains, exhibit much higher activity of removing fuzz from cotton fabrics than the 40 KDa protein RCE I-H4 (40 KDa), which has the cellulose-binding domain (CBD). This indicates that the RCE I protein, which lacks the cellulose-binding domain (CBD), exhibits much higher activity of removing fuzz from cotton fabrics than the 40 KDa protein, which has the cellulose-binding domain (CBD), regardless the length of the linker domain remaining on the N-terminal side of the catalytic active domain. Also, whether or not it is an artificial or non-artificial deficiency, the RCE I protein, which lacks the cellulose-binding domain (CBD), exhibits much higher activity of removing fuzz from cotton fabrics than the 40 KDa protein RCE I-H4 (40 KDa), which has the cellulose-binding domain (CBD).

[Example 10] Comparison of specific activity of removing fuzz from lyocell fabric among various purified RCE I proteins, which lack the cellulose-binding domains

[0147] Using the endoglucanase which was homogenously purified in Example 5, a lyocell fabric (6 cm x 8 cm, Toyoshima Japan) was subjected to fuzz removal under conditions improved from the method described in Example 4. The amount of fuzz remaining unremoved was visually evaluated, and the amount of purified enzyme required to completely remove fuzz was determined. The amount of protein was determined using the BCA Protein Assay Reagent (PIERCE) in accordance with the conditions described in the attached manual. The estimated molecular weight of the 40 KDa purified RCE I protein (RCE I-H4 (40 KDa)) is about 1.5 times higher than those of the 25 KDa purified RCE I proteins (RCE I-H43 (25 KDa)), RCE I-H45 (25 KDa)), and RCE I-H4 (25 KDa)). Accordingly, even though the quantified amounts of proteins are the same, the number of enzyme molecules in the 40 KDa purified RCE I protein is only about two-thirds of that in the 25 KDa purified RCE I protein in terms of the number of enzyme molecules contained in the protein.

Test machine: Launder Meter L-20 (Daiei Kagaku Seiki MFG, Japan)

Temperature: 40°C

Time: 90 minutes

Reaction volume: 40 ml

Reaction pH: Reacted at pH 6 (10 mM acetate buffer, prepared using deionized water).

[0148] The treating liquid contained 4 rubber balls (about 16 g each) together with the enzyme solution.

[0149] The results are as shown in Table 6 below.

Table 6

	The amount of enzyme added
Purified RCE I-H4 (40 KDa)	32 µg
Purified RCE I-H43 (25 KDa)	12 µg

Table 6 (continued)

	The amount of enzyme added
Purified RCE I-H45 (25 KDa)	11 µg
Purified RCE I-H4 (25 KDa)	11 µg

[0150] As is apparent from the results shown in Table 6, various RCE I proteins such as RCE I-H43 (25 KDa), RCE I-H-45 (25 KDa), and RCE I-H4 (25 KDa), which lack the cellulose-binding domains, exhibit higher activity of removing fuzz from lyocell fabrics than the 40 KDa protein RCE I-H4 (40 KDa), which has the cellulose-binding domain (CBD). This indicates that the RCE I protein, which lacks the cellulose-binding domain (CBD), exhibits higher activity of removing fuzz from lyocell fabrics than the 40 KDa protein, which has the cellulose-binding domain (CBD) regardless the length of the linker domain remaining on the N-terminal side of the catalytic active domain. Also, whether or not it is an artificial or non-artificial deficiency, the RCE I protein, which lacks the cellulose-binding domain (CBD), exhibits higher activity of removing fuzz from lyocell fabrics than the 40 KDa protein RCE I-H4 (40 KDa), which has the cellulose-binding domain (CBD).

[0151] All publications, patents, and patent applications cited herein are incorporated herein by reference in their entirety.

#### Industrial Applicability

[0152] When Zygomycetes-derived endoglucanase such as RCE I, RCE II, RCE III, MCE I, MCE II, or PCE I, which lacks the cellulose-binding domain, is allowed to act, the endoglucanase activity can be significantly enhanced in comparison with endoglucanase having a cellulose-binding domain. Accordingly, fabric treatment such as reduction of fuzzing, improvement in feel and appearance, color clarification, partial color change, and softening of cellulose-containing fabrics and improvement in deinking of waste paper and drainage of paper pulp can be effected with a smaller amount of enzymes. This can decrease necessary costs remarkably.

#### Free Text of Sequence Listings

#### [0153]

SEQ ID NO: 13: codon optimized sequence corresponding to RCE I protein (SEQ ID NO: 2)  
 SEQ ID NO: 17: consensus amino acid sequence found in the cellulose-binding domain of family 45 endoglucanase  
 SEQ ID NO: 20 to 23: primers  
 SEQ ID NO: 24: recombinant protein  
 SEQ ID NO: 25 to 28: primers  
 SEQ ID NO: 29: recombinant protein  
 SEQ ID NO: 30 to 35: N-terminal amino acid sequence of recombinant protein  
 SEQ ID NO: 36 and 37: primers  
 SEQ ID NO: 38: NCE5 amino acid sequence  
 SEQ ID NO: 39: NCE5 cDNA sequence  
 SEQ ID NO: 40 to 43: primers

SEQUENCE LISTING

5

<110> MEIJI SEIKA KAISHA, LTD.

10

<120> Endoglucanase Enzyme from Zygomycetes Having Deletion of  
Cellulose Binding Domain

15

<130> PH-1443-PCT

20

<150> JP2000-354296

<151> 2000-11-21

25

<160> 43

30

<170> PatentIn Ver. 2.0

<210> 1

35

<211> 338

<212> PRT

<213> Rhizopus oryzae CP96001

40

<220>

45

<221> sig#peptide

<222> (-23)... (-1)

50

<220>

<221> mat#peptide

55

<222> (1)... (315)

&lt;400&gt; 1

5 Met Lys Phe Ile Thr Ile Ala Ser Ser Ala Leu Leu Ala Leu Ala Leu  
                   -20                  -15                  -10  
 Gly Thr Glu Met Ala Ser Ala Ala Glu Cys Ser Lys Leu Tyr Gly Gln  
 10               -5                  1                  5  
 Cys Gly Gly Lys Asn Trp Asn Gly Pro Thr Cys Cys Glu Ser Gly Ser  
           10                  15                  20                  25  
 15 Thr Cys Lys Val Ser Asn Asp Tyr Tyr Ser Gln Cys Leu Pro Ser Gly  
                   30                  35                  40  
 20 Ser Ser Gly Asn Lys Ser Ser Glu Ser Ala His Lys Lys Thr Thr Thr  
                   45                  50                  55  
 Ala Ala His Lys Lys Thr Thr Thr Ala Ala His Lys Lys Thr Thr Thr  
 25               60                  65                  70  
 Ala Pro Ala Lys Lys Thr Thr Thr Val Ala Lys Ala Ser Thr Pro Ser  
           75                  80                  85  
 30 Asn Ser Ser Ser Ser Ser Ser Gly Lys Tyr Ser Ala Val Ser Gly Gly  
           90                  95                  100                  105  
 35 Ala Ser Gly Asn Gly Val Thr Thr Arg Tyr Trp Asp Cys Cys Lys Ala  
                   110                  115                  120  
 Ser Cys Ser Trp Pro Gly Lys Ala Asn Val Ser Ser Pro Val Lys Ser  
 40               125                  130                  135  
 Cys Asn Lys Asp Gly Val Thr Ala Leu Ser Asp Ser Asn Ala Gln Ser  
           140                  145                  150  
 45 Gly Cys Asn Gly Gly Asn Ser Tyr Met Cys Asn Asp Asn Gln Pro Trp  
           155                  160                  165  
 50 Ala Val Asn Asp Asn Leu Ala Tyr Gly Phe Ala Ala Ala Ala Ile Ser  
           170                  175                  180                  185  
 Gly Gly Gly Glu Ser Arg Trp Cys Cys Ser Cys Phe Glu Leu Thr Phe  
 55               190                  195                  200



Thr Ser Thr Ser Val Ala Gly Lys Lys Met Val Val Gln Val Thr Asn  
 205 210 215  
 Thr Gly Gly Asp Leu Gly Ser Ser Thr Gly Ala His Phe Asp Leu Gln  
 220 225 230  
 Met Pro Gly Gly Gly Val Gly Ile Phe Asn Gly Cys Ser Ser Gln Trp  
 235 240 245  
 Gly Ala Pro Asn Asp Gly Trp Gly Ser Arg Tyr Gly Gly Ile Ser Ser  
 250 255 260 265  
 Ala Ser Asp Cys Ser Ser Leu Pro Ser Ala Leu Gln Ala Gly Cys Lys  
 270 275 280  
 Trp Arg Phe Asn Trp Phe Lys Asn Ala Asp Asn Pro Ser Met Thr Tyr  
 285 290 295  
 Lys Glu Val Thr Cys Pro Lys Glu Ile Thr Ala Lys Thr Gly Cys Ser  
 300 305 310  
 Arg Lys  
 315

<210> 2  
 <211> 1017  
 <212> DNA  
 <213> Rhizopus oryzae CP96001

<220>  
 <221> sig#peptide  
 <222> (1)... (69)

<220>  
 <221> mat#peptide  
 <222> (70)... (1017)

&lt;400&gt; 2

5 atg aag ttt att act att gcc tct tcc gct ctc ttg gct ctc gcc ctc 48  
 Met Lys Phe Ile Thr Ile Ala Ser Ser Ala Leu Leu Ala Leu Ala Leu  
 10 -20 -15 -10  
 ggt act gaa atg gcc tct gct gct gaa tgt agc aaa ttg tat ggt caa 96  
 Gly Thr Glu Met Ala Ser Ala Ala Glu Cys Ser Lys Leu Tyr Gly Gln  
 15 -5 1 5  
 tgt ggt ggt aag aac tgg aat ggc cct act tgt tgt gaa tct gga tcc 144  
 Cys Gly Gly Lys Asn Trp Asn Gly Pro Thr Cys Cys Glu Ser Gly Ser  
 20 10 15 20 25  
 acc tgt aaa gta agc aac gat tac tac tct caa tgt ctt ccc tct gga 192  
 Thr Cys Lys Val Ser Asn Asp Tyr Tyr Ser Gln Cys Leu Pro Ser Gly  
 25 30 35 40  
 agc agt ggc aat aaa tct tct gaa agt gct cac aag aag act acc act 240  
 Ser Ser Gly Asn Lys Ser Ser Glu Ser Ala His Lys Lys Thr Thr Thr  
 30 45 50 55  
 gct gct cac aag aag act act acc gct gct cat aaa aag act acc act 288  
 Ala Ala His Lys Lys Thr Thr Thr Ala Ala His Lys Lys Thr Thr Thr  
 35 60 65 70  
 gct cct gct aag aag act aca act gtt gcc aaa gct tcc acc cct tct 336  
 Ala Pro Ala Lys Lys Thr Thr Thr Val Ala Lys Ala Ser Thr Pro Ser  
 40 75 80 85  
 aac tct agc tct agc tcc agc ggc aaa tat tcc gct gtc tct ggt ggt 384  
 Asn Ser Ser Ser Ser Ser Ser Gly Lys Tyr Ser Ala Val Ser Gly Gly  
 45 90 95 100 105  
 gcc tct ggt aac ggt gtc act act cgt tat tgg gat tgc tgt aag gcc 432  
 Ala Ser Gly Asn Gly Val Thr Thr Arg Tyr Trp Asp Cys Cys Lys Ala  
 50 110 115 120  
 55

tcc tgt agc tgg ccc ggt aag gcc aat gtc agt tct cct gtc aag tcc 480  
 Ser Cys Ser Trp Pro Gly Lys Ala Asn Val Ser Ser Pro Val Lys Ser  
 5 125 130 135  
 tgt aac aaa gat ggt gtc act gcc ctt agt gac agc aat gcc caa agt 528  
 10 Cys Asn Lys Asp Gly Val Thr Ala Leu Ser Asp Ser Asn Ala Gln Ser  
 140 145 150  
 ggc tgt aac ggt ggt aac agt tac atg tgt aac gac aac caa cct tgg 576  
 15 Gly Cys Asn Gly Gly Asn Ser Tyr Met Cys Asn Asp Asn Gln Pro Trp  
 155 160 165  
 gct gta aac gac aac ctt gcc tat ggt ttc gct gct gct gcc atc agt 624  
 20 Ala Val Asn Asp Asn Leu Ala Tyr Gly Phe Ala Ala Ala Ala Ile Ser  
 170 175 180 185  
 ggt ggt ggt gaa tct cgc tgg tgc tgt tct tgt ttc gaa ctt act ttc 672  
 25 Gly Gly Gly Glu Ser Arg Trp Cys Cys Ser Cys Phe Glu Leu Thr Phe  
 190 195 200  
 act tct acc tct gtt gct ggt aag aag atg gtt gtc caa gtc act aac 720  
 30 Thr Ser Thr Ser Val Ala Gly Lys Lys Met Val Val Gln Val Thr Asn  
 205 210 215  
 act ggt ggt gat ctt ggc tcc tct act ggt gct cac ttt gac ttg caa 768  
 35 Thr Gly Gly Asp Leu Gly Ser Ser Thr Gly Ala His Phe Asp Leu Gln  
 220 225 230  
 atg ccc ggt ggt ggt gtt ggt att ttc aat ggt tgt tcc agc caa tgg 816  
 40 Met Pro Gly Gly Gly Val Gly Ile Phe Asn Gly Cys Ser Ser Gln Trp  
 235 240 245  
 ggt gct ccc aat gac ggt tgg ggc tca aga tac ggt ggt att tct tct 864  
 50 Gly Ala Pro Asn Asp Gly Trp Gly Ser Arg Tyr Gly Gly Ile Ser Ser  
 250 255 260 265  
 gca tct gac tgc tct agt ctt cct tcc gca ctc caa gct ggt tgt aaa 912  
 55 Ala Ser Asp Cys Ser Ser Leu Pro Ser Ala Leu Gln Ala Gly Cys Lys

270 275 280  
 5 tgg aga ttc aac tgg ttc aag aac gct gat aac cca agc atg act tac 960  
 Trp Arg Phe Asn Trp Phe Lys Asn Ala Asp Asn Pro Ser Met Thr Tyr  
 285 290 295  
 10 aag gaa gtt acc tgt cct aag gaa atc acc gcc aag aca ggt tgt tca 1008  
 Lys Glu Val Thr Cys Pro Lys Glu Ile Thr Ala Lys Thr Gly Cys Ser  
 300 305 310  
 15 aga aaa taa 1017  
 Arg Lys  
 20 315  
 <210> 3  
 25 <211> 366  
 <212> PRT  
 <213> Rhizopus oryzae CP96001  
 30  
 <220>  
 <221> sig#peptide  
 35 <222> (-23)... (-1)  
 <220>  
 40 <221> mat#peptide  
 <222> (1)... (343)  
 45  
 <400> 3  
 50 Met Lys Phe Ile Thr Ile Thr Ser Ser Ala Leu Leu Ala Leu Ala Leu  
 -20 -15 -10  
 Gly Thr Glu Met Ala Ser Ala Ala Lys Cys Ser Lys Leu Tyr Gly Gln  
 55 -5 1 5

Cys Gly Gly Lys Asp Trp Asn Gly Pro Thr Cys Cys Glu Ser Gly Ser  
 5           10                   15                   20                   25  
 Thr Cys Lys Val Ser Asn Asp Tyr Tyr Ser Gln Cys Leu Ala Pro Glu  
                  30                   35                   40  
 10 Ser Asn Gly Asn Lys Ser Ser Glu Cys Ser Lys Leu Tyr Gly Gln Cys  
                  45                   50                   55  
 15 Gly Gly Lys Asp Trp Asn Gly Pro Thr Cys Cys Glu Ser Gly Ser Thr  
                  60                   65                   70  
 Cys Lys Val Ser Asn Asp Tyr Tyr Ser Gln Cys Leu Ala Pro Glu Ser  
 20           75                   80                   85  
 Asn Gly Asn Lys Thr Ser Glu Ser Ala His Lys Thr Thr Thr Thr Thr  
   90                   95                   100                   105  
 25 Ala Pro Ala Lys Glu Ile Thr Thr Thr Ala Lys Ala Ser Asn Ser Ser  
                  110                   115                   120  
 Asn Ser Ser Gly Lys Tyr Ser Ile Val Ser Gly Gly Ala Ser Gly Asn  
 30           125                   130                   135  
 Gly Val Thr Thr Arg Tyr Trp Asp Cys Cys Lys Ala Ser Cys Ser Trp  
          140                   145                   150  
 35 Pro Gly Lys Ala Asn Val Ser Ser Pro Val Lys Ser Cys Asn Lys Asp  
          155                   160                   165  
 40 Gly Val Thr Ala Leu Ser Asp Ser Asn Val Gln Ser Gly Cys Asn Gly  
   170                   175                   180                   185  
 Gly Asn Ser Tyr Met Cys Asn Asp Asn Gln Pro Trp Ala Val Asn Asp  
 45                   190                   195                   200  
 Asn Leu Ala Tyr Gly Phe Ala Ala Ala Ala Ile Ser Gly Gly Gly Glu  
          205                   210                   215  
 50 Ser Arg Trp Cys Cys Ser Cys Phe Glu Leu Thr Phe Thr Ser Thr Ser  
          220                   225                   230  
 55 Val Ala Gly Lys Lys Met Val Ile Gln Val Thr Asn Thr Gly Gly Asp

235                      240                      245  
 5    Leu Gly Ser Ser Thr Gly Ala His Phe Asp Leu Gln Met Pro Gly Gly  
     250                      255                      260                      265  
     Gly Val Gly Ile Phe Asn Gly Cys Ser Lys Gln Trp Gly Ala Pro Asn  
 10                      270                      275                      280  
     Asp Gly Trp Gly Ser Arg Tyr Gly Gly Ile Ser Ser Ala Ser Asp Cys  
                     285                      290                      295  
 15    Ser Ser Leu Pro Ser Ala Leu Gln Ala Gly Cys Lys Trp Arg Phe Asn  
                     300                      305                      310  
 20    Trp Phe Lys Asn Ala Asp Asn Pro Ser Met Thr Tyr Lys Glu Val Thr  
                     315                      320                      325  
     Cys Pro Lys Glu Ile Thr Ala Lys Thr Gly Cys Ser Arg Lys  
 25    330                      335                      340  
  
 30    <210> 4  
     <211> 1101  
     <212> DNA  
 35    <213> Rhizopus oryzae CP96001  
  
     <220>  
 40    <221> sig#peptide  
     <222> (1)... (69)  
  
 45    <220>  
     <221> mat#peptide  
     <222> (70)... (1101)  
 50  
  
     <400> 4  
 55    atg aag ttt att act att acc tct tcc gct ctc ttg gct ctc gcc ctt    48

	Met Lys Phe Ile Thr Ile Thr Ser Ser Ala Leu Leu Ala Leu Ala Leu	
	-20 -15 -10	
5	ggt act gaa atg gcc tct gct gct aaa tgt agc aag ctg tat ggt caa	96
	Gly Thr Glu Met Ala Ser Ala Ala Lys Cys Ser Lys Leu Tyr Gly Gln	
10	-5 1 5	
	tgt ggt ggt aag gac tgg aat ggc cct act tgt tgc gaa tct gga tcc	144
	Cys Gly Gly Lys Asp Trp Asn Gly Pro Thr Cys Cys Glu Ser Gly Ser	
15	10 15 20 25	
	acc tgt aaa gta agc aac gat tac tac tct caa tgt ctt gcc cct gaa	192
	Thr Cys Lys Val Ser Asn Asp Tyr Tyr Ser Gln Cys Leu Ala Pro Glu	
20	30 35 40	
	agc aac ggc aat aag tct tct gaa tgt agc aag ttg tat ggt caa tgt	240
25	Ser Asn Gly Asn Lys Ser Ser Glu Cys Ser Lys Leu Tyr Gly Gln Cys	
	45 50 55	
	ggt ggt aag gac tgg aat ggc cct act tgt tgc gaa tct gga tcc acc	288
30	Gly Gly Lys Asp Trp Asn Gly Pro Thr Cys Cys Glu Ser Gly Ser Thr	
	60 65 70	
	tgt aaa gta agc aac gat tac tac tct caa tgt ctt gcc cct gaa agc	336
35	Cys Lys Val Ser Asn Asp Tyr Tyr Ser Gln Cys Leu Ala Pro Glu Ser	
	75 80 85	
	aat ggc aat aaa act tct gaa agc gct cat aaa acg act act acc act	384
40	Asn Gly Asn Lys Thr Ser Glu Ser Ala His Lys Thr Thr Thr Thr Thr	
	90 95 100 105	
	gct ccc gct aag gaa att aca act act gcc aaa gct tca aac tct tct	432
45	Ala Pro Ala Lys Glu Ile Thr Thr Thr Ala Lys Ala Ser Asn Ser Ser	
	110 115 120	
50	aac tct agc ggc aaa tac tcc att gtc tct ggt ggt gcc tct ggt aac	480
	Asn Ser Ser Gly Lys Tyr Ser Ile Val Ser Gly Gly Ala Ser Gly Asn	
55	125 130 135	

5      ggt gtc act act cgt tat tgg gat tgc tgt aag gcc tcc tgt agc tgg    528  
      Gly Val Thr Thr Arg Tyr Trp Asp Cys Cys Lys Ala Ser Cys Ser Trp  
          140                      145                      150  
 10      ccc ggt aag gcc aat gtc agt tct cct gtc aag tcc tgt aac aaa gat    576  
      Pro Gly Lys Ala Asn Val Ser Ser Pro Val Lys Ser Cys Asn Lys Asp  
          155                      160                      165  
 15      ggt gtc act gcc ctt agt gac agc aat gtc caa agt ggc tgt aac ggt    624  
      Gly Val Thr Ala Leu Ser Asp Ser Asn Val Gln Ser Gly Cys Asn Gly  
          170                      175                      180                      185  
 20      ggt aac agt tac atg tgt aac gac aac cag cct tgg gct gta aac gat    672  
      Gly Asn Ser Tyr Met Cys Asn Asp Asn Gln Pro Trp Ala Val Asn Asp  
          190                      195                      200  
 25      aat ctt gcc tat ggt ttc gct gct gct gcc atc agt ggt ggt ggt gaa    720  
      Asn Leu Ala Tyr Gly Phe Ala Ala Ala Ala Ile Ser Gly Gly Gly Glu  
          205                      210                      215  
 30      tct cgc tgg tgc tgt tct tgt ttc gaa ctt act ttc act tct acc tct    768  
      Ser Arg Trp Cys Cys Ser Cys Phe Glu Leu Thr Phe Thr Ser Thr Ser  
          220                      225                      230  
 35      gtt gct ggt aag aag atg gtt atc caa gtc act aac act ggt ggt gat    816  
      Val Ala Gly Lys Lys Met Val Ile Gln Val Thr Asn Thr Gly Gly Asp  
          235                      240                      245  
 40      ctt ggc tcc tct act ggt gct cac ttt gac ttg caa atg ccc ggt ggt    864  
      Leu Gly Ser Ser Thr Gly Ala His Phe Asp Leu Gln Met Pro Gly Gly  
          250                      255                      260                      265  
 45      ggt gtt ggt att ttc aat ggt tgc tcc aag caa tgg ggt gct ccc aat    912  
      Gly Val Gly Ile Phe Asn Gly Cys Ser Lys Gln Trp Gly Ala Pro Asn  
          270                      275                      280  
 50      gac ggt tgg ggc tgc aga tac ggt ggt att tct tct gca tct gac tgc    960  
      Asp Gly Trp Gly Ser Arg Tyr Gly Gly Ile Ser Ser Ala Ser Asp Cys  
 55



285                      290                      295  
 5    tct agt ctt cct tcc gca ctc caa gct ggt tgt aaa tgg aga ttc aac 1008  
     Ser Ser Leu Pro Ser Ala Leu Gln Ala Gly Cys Lys Trp Arg Phe Asn  
          300                      305                      310  
 10    tgg ttc aag aac gct gat aac cca agc atg act tac aag gaa gtt acc 1056  
     Trp Phe Lys Asn Ala Asp Asn Pro Ser Met Thr Tyr Lys Glu Val Thr  
          315                      320                      325  
 15    tgt ccc aag gaa atc acc gcc aag aca ggt tgt tca aga aaa taa 1101  
     Cys Pro Lys Glu Ile Thr Ala Lys Thr Gly Cys Ser Arg Lys  
 20    330                      335                      340

<210> 5

<211> 360

<212> PRT

<213> Rhizopus oryzae CP96001

<220>

<221> sig#peptide

<222> (-23)... (-1)

<220>

<221> mat#peptide

<222> (1)... (337)

<400> 5

Met Lys Phe Leu Thr Ile Ala Ser Ser Ala Ile Leu Ala Leu Ala Val

-20

-15

-10

Gly Thr Glu Met Ala His Ala Ala Glu Cys Ser Lys Ala Tyr Tyr Gln

-5

1

5

Cys Gly Gly Lys Asn Trp Asp Gly Pro Thr Cys Cys Glu Ser Gly Ser  
 10 15 20 25  
 5 Thr Cys Val Asp Tyr Pro Asp Asn Pro Phe Tyr Ser Gln Cys Val Pro  
 30 35 40  
 10 Asn Glu Asn Leu Thr Ser Thr Asn Lys Ser Ser His Lys Thr Thr Thr  
 45 50 55  
 15 Thr Glu Ser Ala Lys Lys Thr Thr Thr Thr Lys Gly Ser Lys Lys Thr  
 60 65 70  
 Thr Thr Thr Glu Ala Ser Lys Lys Thr Thr Thr Thr Glu Ala Ser Lys  
 75 80 85  
 20 Lys Thr Thr Thr Thr Glu Ala Ser Lys Lys Thr Thr Thr Thr Thr Lys  
 90 95 100 105  
 25 Lys Ala Ser Thr Ser Thr Ser Ser Ser Ser Ser Ser Ala Ser Thr Asn  
 110 115 120  
 Tyr Ser Ala Val Ser Gly Gly Ala Ser Gly Asn Gly Glu Thr Thr Arg  
 125 130 135  
 30 Tyr Trp Asp Cys Cys Lys Pro Ser Cys Ser Trp Pro Gly Lys Ala Asp  
 140 145 150  
 35 Val Thr Ser Pro Val Gly Ser Cys Asn Lys Asp Gly Lys Thr Leu Ala  
 155 160 165  
 40 Asp Asn Asn Thr Gln Asn Gly Cys Val Gly Gly Ser Ser Tyr Thr Cys  
 170 175 180 185  
 Asn Asp Asn Gln Pro Trp Val Val Ser Asp Asp Leu Ala Tyr Gly Phe  
 190 195 200  
 45 Ala Ala Ala Ser Ile Ser Gly Gly Ser Glu Ala Thr Trp Cys Cys Ala  
 205 210 215  
 50 Cys Phe Glu Leu Thr Phe Thr Ser Thr Ala Val Lys Gly Lys Lys Met  
 220 225 230  
 55 Val Val Gln Val Thr Asn Thr Gly Ser Asp Leu Gly Ser Asn Thr Gly

235                      240                      245  
 5    Ala His Phe Asp Leu Gln Met Pro Gly Gly Gly Val Gly Ile Tyr Asn  
     250                      255                      260                      265  
     Gly Cys Ala Thr Gln Trp Gly Ala Pro Thr Asp Gly Trp Gly Ala Arg  
 10                      270                      275                      280  
     Tyr Gly Gly Val Ser Ser Ala Ser Asp Cys Ser Asn Leu Pro Ser Ala  
                     285                      290                      295  
 15    Leu Gln Ala Gly Cys Lys Trp Arg Phe Gly Trp Phe Lys Asn Ala Asp  
                     300                      305                      310  
 20    Asn Pro Thr Met Thr Tyr Lys Gln Val Thr Cys Pro Lys Ala Ile Thr  
                     315                      320                      325  
     Ala Lys Ser Gly Cys Ser Arg Lys  
 25    330                      335  
  
 30    <210> 6  
     <211> 1083  
     <212> DNA  
     <213> Rhizopus oryzae CP96001  
 35  
  
     <220>  
 40    <221> sig#peptide  
     <222> (1)... (69)  
  
 45    <220>  
     <221> mat#peptide  
     <222> (70)... (1083)  
 50  
  
     <400> 6  
 55    atg aag ttc ctt acc att gcc tcc tcc gct atc ttg gca ctt gcc gtc    48

	Met Lys Phe Leu Thr Ile Ala Ser Ser Ala Ile Leu Ala Leu Ala Val	
	-20 -15 -10	
5	ggc act gaa atg gcc cat gct gct gaa tgt agc aag gct tac tac caa	96
	Gly Thr Glu Met Ala His Ala Ala Glu Cys Ser Lys Ala Tyr Tyr Gln	
10	-5 1 5	
	tgt ggt ggt aag aac tgg gat gga cct acc tgc tgt gaa tct ggc tct	144
	Cys Gly Gly Lys Asn Trp Asp Gly Pro Thr Cys Cys Glu Ser Gly Ser	
15	10 15 20 25	
	act tgc gtt gat tat cct gac aat cct ttc tac tcc caa tgt gtt ccc	192
	Thr Cys Val Asp Tyr Pro Asp Asn Pro Phe Tyr Ser Gln Cys Val Pro	
20	30 35 40	
	aat gaa aac ctc acc tcc act aac aaa tct tct cac aaa acc acc act	240
25	Asn Glu Asn Leu Thr Ser Thr Asn Lys Ser Ser His Lys Thr Thr Thr	
	45 50 55	
	act gag agt gcc aag aag act acc act act aaa ggt tcc aag aag acc	288
30	Thr Glu Ser Ala Lys Lys Thr Thr Thr Thr Lys Gly Ser Lys Lys Thr	
	60 65 70	
	acc act act gaa gcc tct aag aag acc acc act act gaa gct tcc aag	336
35	Thr Thr Thr Glu Ala Ser Lys Lys Thr Thr Thr Thr Glu Ala Ser Lys	
	75 80 85	
	aag acc acc act act gaa gcc tct aag aag acc acc act act act aag	384
40	Lys Thr Thr Thr Thr Glu Ala Ser Lys Lys Thr Thr Thr Thr Thr Lys	
	90 95 100 105	
45	aag gct tct acc tcc act tcc tct tcc tct tct tct gct tct aca aac	432
	Lys Ala Ser Thr Ser Thr Ser Ser Ser Ser Ser Ser Ala Ser Thr Asn	
	110 115 120	
50	tac tcc gct gtc tct ggt ggt gcc tcc ggt aat ggt gaa acc act cgc	480
	Tyr Ser Ala Val Ser Gly Gly Ala Ser Gly Asn Gly Glu Thr Thr Arg	
55	125 130 135	

5      tac tgg gat tgt tgt aag cct tct tgc agt tgg ccc ggt aag gct gat    528  
      Tyr Trp Asp Cys Cys Lys Pro Ser Cys Ser Trp Pro Gly Lys Ala Asp  
          140                      145                      150  
 10      gtc acc tcc cct gtt ggc tcc tgt aac aag gat ggt aag act ctt gct    576  
      Val Thr Ser Pro Val Gly Ser Cys Asn Lys Asp Gly Lys Thr Leu Ala  
          155                      160                      165  
 15      gat aac aac act caa aac ggc tgt gtt ggt ggt agc agc tac acc tgt    624  
      Asp Asn Asn Thr Gln Asn Gly Cys Val Gly Gly Ser Ser Tyr Thr Cys  
          170                      175                      180                      185  
 20      aat gac aat caa cct tgg gtt gtt agc gac gac ctt gcc tac ggt ttc    672  
      Asn Asp Asn Gln Pro Trp Val Val Ser Asp Asp Leu Ala Tyr Gly Phe  
          190                      195                      200  
 25      gcc gct gct tcc att tct ggt ggt agc gaa gct act tgg tgt tgt gcc    720  
      Ala Ala Ala Ser Ile Ser Gly Gly Ser Glu Ala Thr Trp Cys Cys Ala  
          205                      210                      215  
 30      tgt ttc gaa ctc aca ttc acc tct act gcc gtc aag ggt aag aag atg    768  
      Cys Phe Glu Leu Thr Phe Thr Ser Thr Ala Val Lys Gly Lys Lys Met  
          220                      225                      230  
 35      gtt gtt caa gta acc aac act ggt tct gac ctt ggc tct aac act ggt    816  
      Val Val Gln Val Thr Asn Thr Gly Ser Asp Leu Gly Ser Asn Thr Gly  
          235                      240                      245  
 40      gct cac ttt gac ttg caa atg ccc ggt ggt ggt gtt ggt atc tac aat    864  
      Ala His Phe Asp Leu Gln Met Pro Gly Gly Gly Val Gly Ile Tyr Asn  
          250                      255                      260                      265  
 45      ggt tgt gcc act caa tgg ggt gct ccc acc gat ggt tgg ggt gca aga    912  
      Gly Cys Ala Thr Gln Trp Gly Ala Pro Thr Asp Gly Trp Gly Ala Arg  
          270                      275                      280  
 50      tac ggc ggt gtt tct tct gcc tct gac tgt tct aac ctt cct tct gcc    960  
      Tyr Gly Gly Val Ser Ser Ala Ser Asp Cys Ser Asn Leu Pro Ser Ala  
 55

285                      290                      295  
 5      ctt caa gct ggt tgt aag tgg aga ttc ggc tgg ttc aaa aac gct gat 1008  
       Leu Gln Ala Gly Cys Lys Trp Arg Phe Gly Trp Phe Lys Asn Ala Asp  
          300                      305                      310  
 10      aac cca acc atg acc tac aaa caa gtt acc tgt ccc aag gct atc act 1056  
       Asn Pro Thr Met Thr Tyr Lys Gln Val Thr Cys Pro Lys Ala Ile Thr  
          315                      320                      325  
 15      gcc aag tct ggc tgt tca aga aaa taa                      1083  
       Ala Lys Ser Gly Cys Ser Arg Lys  
          330                      335  
 20  
       <210> 7  
 25      <211> 338  
       <212> PRT  
       <213> Mucor circinelloides CP99001  
 30  
       <220>  
       <221> sig#peptide  
 35      <222> (-22)... (-1)  
       <220>  
 40      <221> mat#peptide  
       <222> (1)... (316)  
 45  
       <400> 7  
       Met Lys Phe Thr Val Ala Ile Thr Ser Ile Ala Val Ala Leu Ala Leu  
 50               -20                      -15                      -10  
       Ser Ser Ser Ala Glu Ala Ala Ser Cys Ser Ser Val Tyr Gly Gln Cys  
          -5                      1                      5                      10  
 55

	Gly Gly Ile Gly Trp Ser Gly Pro Thr Cys Cys Glu Ser Gly Ser Thr
5	15 20 25
	Cys Val Ala Gln Glu Gly Asn Lys Tyr Tyr Ser Gln Cys Leu Pro Gly
	30 35 40
10	Ser His Ser Asn Asn Ala Gly Asn Ala Ser Ser Thr Lys Lys Thr Ser
	45 50 55
15	Thr Lys Thr Ser Thr Thr Thr Ala Lys Ala Thr Ala Thr Val Thr Thr
	60 65 70
	Lys Thr Val Thr Lys Thr Thr Thr Lys Thr Thr Thr Lys Thr Ser Thr
20	75 80 85 90
	Thr Ala Ala Ala Ser Thr Ser Thr Ser Ser Ser Ala Gly Tyr Lys Val
	95 100 105
25	Ile Ser Gly Gly Lys Ser Gly Ser Gly Ser Thr Thr Arg Tyr Trp Asp
	110 115 120
	Cys Cys Lys Ala Ser Cys Ser Trp Pro Gly Lys Ala Ser Val Thr Gly
30	125 130 135
	Pro Val Asp Thr Cys Ala Ser Asn Gly Ile Ser Leu Leu Asp Ala Asn
	140 145 150
35	Ala Gln Ser Gly Cys Asn Gly Gly Asn Gly Phe Met Cys Asn Asn Asn
	155 160 165 170
40	Gln Pro Trp Ala Val Asn Asp Glu Leu Ala Tyr Gly Phe Ala Ala Ala
	175 180 185
	Ser Ile Ala Gly Ser Asn Glu Ala Gly Trp Cys Cys Gly Cys Tyr Glu
45	190 195 200
	Leu Thr Phe Thr Ser Gly Ala Ala Ser Gly Lys Lys Met Val Val Gln
	205 210 215
50	Val Thr Asn Thr Gly Gly Asp Leu Gly Ser Asn His Phe Asp Leu Gln
	220 225 230
55	Met Pro Gly Gly Gly Val Gly Ile Phe Asn Gly Cys Ala Ala Gln Trp

235                      240                      245                      250  
 5 Gly Ala Pro Asn Asp Gly Trp Gly Ala Arg Tyr Gly Gly Val Ser Ser  
                          255                      260                      265  
 Val Ser Asp Cys Ala Ser Leu Pro Ser Ala Leu Gln Ala Gly Cys Lys  
 10                      270                      275                      280  
 Trp Arg Phe Asn Trp Phe Lys Asn Ser Asp Asn Pro Thr Met Thr Phe  
                          285                      290                      295  
 15 Lys Glu Val Thr Cys Pro Ala Glu Leu Thr Thr Arg Ser Gly Cys Glu  
                          300                      305                      310  
 20 Arg Lys  
 315  
 25 <210> 8  
      <211> 1017  
      <212> DNA  
 30 <213> Mucor circinelloides CP99001  
  
      <220>  
 35 <221> sig#peptide  
      <222> (1)... (66)  
  
 40 <220>  
      <221> mat#peptide  
 45 <222> (67)... (1017)  
  
      <400> 8  
 50 atg aag ttc acc gtt gct att act tca atc gct gtt gca ctc gct ctc    48  
 Met Lys Phe Thr Val Ala Ile Thr Ser Ile Ala Val Ala Leu Ala Leu  
                          -20                      -15                      -10  
 55



EP 1 344 820 A1

agc tct tct gct gaa gct gct tct tgc agc tct gtc tat ggt caa tgt 96  
 Ser Ser Ser Ala Glu Ala Ala Ser Cys Ser Ser Val Tyr Gly Gln Cys  
 5               -5                               1                               5                               10  
 ggt ggc att gga tgg agt gga cct acc tgt tgt gaa agt ggc tct act 144  
 Gly Gly Ile Gly Trp Ser Gly Pro Thr Cys Cys Glu Ser Gly Ser Thr  
 10                               15                               20                               25  
 tgc gtt gct caa gaa ggc aac aaa tac tac tct caa tgt ctt ccc gga 192  
 Cys Val Ala Gln Glu Gly Asn Lys Tyr Tyr Ser Gln Cys Leu Pro Gly  
 15                               30                               35                               40  
 tcc cac agt aac aat gct ggt aac gct agc agc acc aag aag aca tct 240  
 Ser His Ser Asn Asn Ala Gly Asn Ala Ser Ser Thr Lys Lys Thr Ser  
 20                               45                               50                               55  
 acc aag aca tct act acc acc gcc aag gct act gct act gtc acc acc 288  
 Thr Lys Thr Ser Thr Thr Thr Ala Lys Ala Thr Ala Thr Val Thr Thr  
 25                               60                               65                               70  
 aag aca gta acc aag aca act acc aag aca act acc aag act agc act 336  
 Lys Thr Val Thr Lys Thr Thr Thr Lys Thr Thr Thr Lys Thr Ser Thr  
 30                               75                               80                               85                               90  
 act gcc gct gct tct act tcc acc tct tct tct gct ggt tac aag gtc 384  
 Thr Ala Ala Ala Ser Thr Ser Thr Ser Ser Ser Ala Gly Tyr Lys Val  
 35                               95                               100                               105  
 atc tct ggc ggt aaa tct ggc agt ggt tcc aca act cgt tat tgg gat 432  
 Ile Ser Gly Gly Lys Ser Gly Ser Gly Ser Thr Thr Arg Tyr Trp Asp  
 40                               110                               115                               120  
 tgt tgt aaa gct tct tgc agc tgg cct gga aaa gct tct gtc act ggt 480  
 Cys Cys Lys Ala Ser Cys Ser Trp Pro Gly Lys Ala Ser Val Thr Gly  
 45                               125                               130                               135  
 cct gtt gac acc tgt gcc tcc aat ggt atc tct tta tta gat gcc aat 528  
 Pro Val Asp Thr Cys Ala Ser Asn Gly Ile Ser Leu Leu Asp Ala Asn  
 50                               140                               145                               150  
 55

	140	145	150	
5	gct caa agt ggt tgt aac ggt ggt aat ggt ttc atg tgt aac aac aac			576
	Ala Gln Ser Gly Cys Asn Gly Gly Asn Gly Phe Met Cys Asn Asn Asn			
	155	160	165	170
10	caa cct tgg gct gtc aat gat gag ctc gct tac ggt ttc gct gct gcc			624
	Gln Pro Trp Ala Val Asn Asp Glu Leu Ala Tyr Gly Phe Ala Ala Ala			
	175	180	185	
15	tct att gct ggc tcc aac gaa gct gga tgg tgt tgt ggc tgt tat gaa			672
	Ser Ile Ala Gly Ser Asn Glu Ala Gly Trp Cys Cys Gly Cys Tyr Glu			
	190	195	200	
20	ttg acc ttc act tct ggc gct gct tct gga aag aag atg gtt gtt caa			720
	Leu Thr Phe Thr Ser Gly Ala Ala Ser Gly Lys Lys Met Val Val Gln			
	205	210	215	
25	glt acc aac acc ggt ggc gat tta ggc tct aac cac ttt gat ttg caa			768
	Val Thr Asn Thr Gly Gly Asp Leu Gly Ser Asn His Phe Asp Leu Gln			
30	220	225	230	
	atg ccc ggt ggt ggc gtt ggt atc ttc aat ggc tgt gct gct caa tgg			816
	Met Pro Gly Gly Gly Val Gly Ile Phe Asn Gly Cys Ala Ala Gln Trp			
35	235	240	245	250
	ggc gct ccc aat gat ggc tgg gga gct aga tat ggt ggt gtc agc tct			864
	Gly Ala Pro Asn Asp Gly Trp Gly Ala Arg Tyr Gly Gly Val Ser Ser			
40	255	260	265	
	gic tct gac tgt gcc tct ctt ccc tct gct ctt caa gct ggt tgt aaa			912
45	Val Ser Asp Cys Ala Ser Leu Pro Ser Ala Leu Gln Ala Gly Cys Lys			
	270	275	280	
	tgg aga ttc aac tgg ttc aag aac tct gat aac cct acc atg acc ttc			960
50	Trp Arg Phe Asn Trp Phe Lys Asn Ser Asp Asn Pro Thr Met Thr Phe			
	285	290	295	
55	aag gaa gtt acc tgt cct gct gaa tta act act cgc tca ggt tgc gaa			1008

Lys Glu Val Thr Cys Pro Ala Glu Leu Thr Thr Arg Ser Gly Cys Glu  
300 305 310  
aga aag taa 1017  
Arg Lys  
315  
  
<210> 9  
<211> 387  
<212> PRT  
<213> Mucor circinelloides CP99001  
  
<220>  
<221> sig#peptide  
<222> (-22)... (-1)  
  
<220>  
<221> mat#peptide  
<222> (1)... (365)  
  
<400> 9  
Met Lys Phe Thr Val Ala Ile Thr Ser Ile Ala Val Ala Leu Ala Leu  
-20 -15 -10  
Ser Ser Ser Ala Glu Ala Ala Ser Cys Ser Ser Val Tyr Gly Gln Cys  
-5 1 5 10  
Gly Gly Ile Gly Trp Thr Gly Pro Thr Cys Cys Asp Ala Gly Ser Thr  
15 20 25  
Cys Lys Ala Gln Lys Asp Asn Lys Tyr Tyr Ser Gln Cys Ile Pro Lys  
30 35 40  
Pro Lys Gly Ser Ser Ser Ser Ser Ser Cys Ser Ser Val Tyr Ser Gln

	45	50	55
5	Cys Gly Gly Ile Gly Trp Ser Gly Pro Thr Cys Cys Glu Ser Gly Ser		
	60	65	70
	Thr Cys Val Ala Gln Glu Gly Asn Lys Tyr Tyr Ser Gln Cys Leu Pro		
10	75	80	85
	Gly Ser His Ser Asn Asn Ala Gly Asn Ala Ser Ser Thr Lys Lys Thr		
	95	100	105
15	Ser Thr Lys Thr Ser Thr Thr Thr Ala Lys Ala Thr Ala Thr Val Thr		
	110	115	120
	Thr Lys Thr Val Thr Lys Thr Thr Thr Lys Thr Thr Thr Lys Thr Ser		
20	125	130	135
	Thr Thr Ala Ala Ala Ser Thr Ser Thr Ser Ser Ala Gly Tyr Lys		
25	140	145	150
	Val Ile Ser Gly Gly Lys Ser Gly Ser Gly Ser Thr Thr Arg Tyr Trp		
	155	160	165
30	Asp Cys Cys Lys Ala Ser Cys Ser Trp Pro Gly Lys Ala Ser Val Thr		
	175	180	185
	Gly Pro Val Asp Thr Cys Ala Ser Asn Gly Ile Ser Leu Leu Asp Ala		
35	190	195	200
	Asn Ala Gln Ser Gly Cys Asn Gly Gly Asn Gly Phe Met Cys Asn Asn		
	205	210	215
40	Asn Gln Pro Trp Ala Val Asn Asp Glu Leu Ala Tyr Gly Phe Ala Ala		
	220	225	230
45	Ala Ser Ile Ala Gly Ser Asn Glu Ala Gly Trp Cys Cys Gly Cys Tyr		
	235	240	245
	Glu Leu Thr Phe Thr Ser Gly Ala Ala Ser Gly Lys Lys Met Val Val		
50	255	260	265
	Gln Val Thr Asn Thr Gly Gly Asp Leu Gly Ser Asn His Phe Asp Leu		
	270	275	280
55			

5           Gln Met Pro Gly Gly Gly Val Gly Ile Phe Asn Gly Cys Ala Ala Gln  
               285                   290                   295  
 10       Trp Gly Ala Pro Asn Asp Gly Trp Gly Ala Arg Tyr Gly Gly Val Ser  
               300                   305                   310  
 15       Ser Val Ser Asp Cys Ala Ser Leu Pro Ser Ala Leu Gln Ala Gly Cys  
               315                   320                   325                   330  
 20       Lys Trp Arg Phe Asn Trp Phe Lys Asn Ser Asp Asn Pro Thr Met Thr  
                           335                   340                   345  
       Phe Lys Glu Val Thr Cys Pro Ala Glu Leu Thr Thr Arg Ser Gly Cys  
                           350                   355                   360  
 25       Glu Arg Lys  
               365  
 30       <210> 10  
           <211> 1164  
           <212> DNA  
           <213> Mucor circinelloides CP99001  
 35       <220>  
           <221> sig#peptide  
           <222> (1)... (66)  
 40       <220>  
           <221> mat#peptide  
           <222> (67)... (1164)  
 45       <400> 10  
           atg aag ttc acc gtt gct att acf tca atc gct gtt gca ctc gct ctc   48  
           Met Lys Phe Thr Val Ala Ile Thr Ser Ile Ala Val Ala Leu Ala Leu  
 55

	-20	-15	-10	
5	agc tct tct gct gaa gct gct tct tgc agc tct gtc tat ggt caa tgt	96		
	Ser Ser Ser Ala Glu Ala Ala Ser Cys Ser Ser Val Tyr Gly Gln Cys			
	-5	1	5	10
10	ggc ggc att ggc tgg act ggt cct aca tgt tgt gat gct gga tgc acc	144		
	Gly Gly Ile Gly Trp Thr Gly Pro Thr Cys Cys Asp Ala Gly Ser Thr			
	15	20	25	
15	tgt aaa gct caa aag gat aac aaa tat tat tct caa tgt att ccc aaa	192		
	Cys Lys Ala Gln Lys Asp Asn Lys Tyr Tyr Ser Gln Cys Ile Pro Lys			
	30	35	40	
20	ccc aag ggt tcc tcc tca tca tca tca tgt agt tcc gtc tat agt caa	240		
	Pro Lys Gly Ser Ser Ser Ser Ser Ser Cys Ser Ser Val Tyr Ser Gln			
	45	50	55	
25	tgc ggt ggc att gga tgg agt gga cct acc tgt tgt gaa agt ggc tct	288		
	Cys Gly Gly Ile Gly Trp Ser Gly Pro Thr Cys Cys Glu Ser Gly Ser			
	60	65	70	
30	act tgc gtt gct caa gaa ggc aac aaa tac tac tct caa tgt ctt ccc	336		
	Thr Cys Val Ala Gln Glu Gly Asn Lys Tyr Tyr Ser Gln Cys Leu Pro			
	75	80	85	90
35	gga tcc cac agt aac aat gct ggt aac gct agc agc acc aag aag aca	384		
	Gly Ser His Ser Asn Asn Ala Gly Asn Ala Ser Ser Thr Lys Lys Thr			
	95	100	105	
40	tct acc aag aca tct act acc acc gcc aag gct act gct act gtc acc	432		
	Ser Thr Lys Thr Ser Thr Thr Thr Ala Lys Ala Thr Ala Thr Val Thr			
	110	115	120	
45	acc aag aca gla acc aag aca act acc aag aca act acc aag act agc	480		
	Thr Lys Thr Val Thr Lys Thr Thr Thr Lys Thr Thr Thr Lys Thr Ser			
	125	130	135	
50	act act gcc gct gct tct act tcc acc tct tct tct gct ggt tac aag	528		
55				

	Thr Thr Ala Ala Ala Ser Thr Ser Thr Ser Ser Ser Ala Gly Tyr Lys	
	140	145
5	gtc atc tct ggc ggt aaa tct ggc agt ggt tcc aca act cgt tat tgg	576
	Val Ile Ser Gly Gly Lys Ser Gly Ser Gly Ser Thr Thr Arg Tyr Trp	
10	155	160
	gat tgt tgt aaa gct tct tgc agc tgg cct gga aaa gct tct gtc act	624
	Asp Cys Cys Lys Ala Ser Cys Ser Trp Pro Gly Lys Ala Ser Val Thr	
15	175	180
	ggt cct gtt gac acc tgt gcc tcc aat ggt atc tct tta tta gat gcc	672
	Gly Pro Val Asp Thr Cys Ala Ser Asn Gly Ile Ser Leu Leu Asp Ala	
20	190	195
	aat gct caa agt ggt tgt aac ggt ggt aat ggt ttc atg tgt aac aac	720
	Asn Ala Gln Ser Gly Cys Asn Gly Gly Asn Gly Phe Met Cys Asn Asn	
25	205	210
	aac caa cct tgg gct gtc aat gat gag ctc gct tac ggt ttc gct gct	768
	Asn Gln Pro Trp Ala Val Asn Asp Glu Leu Ala Tyr Gly Phe Ala Ala	
30	220	225
	gcc tct att gct ggc tcc aac gaa gct gga tgg tgt tgt ggc tgt tat	816
35	235	240
	Ala Ser Ile Ala Gly Ser Asn Glu Ala Gly Trp Cys Cys Gly Cys Tyr	
	245	250
	gaa ttg acc ttc act tct ggc gct gct tct gga aag aag atg gtt gtt	864
40	Glu Leu Thr Phe Thr Ser Gly Ala Ala Ser Gly Lys Lys Met Val Val	
	255	260
	caa gtt acc aac acc ggt ggc gat tta ggc tct aac cac ttt gat ttg	912
45	Gln Val Thr Asn Thr Gly Gly Asp Leu Gly Ser Asn His Phe Asp Leu	
	270	275
	280	
50	caa atg ccc ggt ggt ggc gtt ggt atc ttc aat ggc tgt gct gct caa	960
	Gln Met Pro Gly Gly Gly Val Gly Ile Phe Asn Gly Cys Ala Ala Gln	
55	285	290
	295	

tgg ggc gct ccc aat gat ggc tgg gga gct aga tat ggt ggt gtc agc 1008  
 5 Trp Gly Ala Pro Asn Asp Gly Trp Gly Ala Arg Tyr Gly Gly Val Ser  
 300 305 310  
 tct gtc tct gac tgt gcc tct ctt ccc tct gct ctt caa gct ggt tgt 1056  
 10 Ser Val Ser Asp Cys Ala Ser Leu Pro Ser Ala Leu Gln Ala Gly Cys  
 315 320 325 330  
 aaa tgg aga ttc aac tgg ttc aag aac tct gat aac cct acc atg acc 1104  
 15 Lys Trp Arg Phe Asn Trp Phe Lys Asn Ser Asp Asn Pro Thr Met Thr  
 335 340 345  
 ttc aag gaa gtt acc tgt cct gct gaa tta act act cgc tca ggt tgc 1152  
 20 Phe Lys Glu Val Thr Cys Pro Ala Glu Leu Thr Thr Arg Ser Gly Cys  
 350 355 360  
 25 gaa aga aag taa 1164  
 Glu Arg Lys  
 365  
 30  
 <210> 11  
 <211> 346  
 35 <212> PRT  
 <213> Phycomyces nitens CP99002  
 40  
 <220>  
 <221> sig#peptide  
 45 <222> (-19)... (-1)  
 50  
 <220>  
 <221> mat#peptide  
 <222> (1)... (327)  
 55



<400> 11

5	Met	Lys	Phe	Ser	Ile	Ile	Ala	Ser	Ala	Leu	Leu	Leu	Ala	Ala	Ser	Ser
					-15					-10					-5	
10	Thr	Tyr	Ala	Ala	Glu	Cys	Ser	Gln	Gly	Tyr	Gly	Gln	Cys	Gly	Gly	Lys
					1				5				10			
15	Met	Trp	Thr	Gly	Pro	Thr	Cys	Cys	Thr	Ser	Gly	Phe	Thr	Cys	Val	Gly
					15				20				25			
20	Ala	Glu	Asn	Asn	Glu	Trp	Tyr	Ser	Gln	Cys	Ile	Pro	Asn	Asp	Gln	Val
					30				35				40			45
25	Gln	Gly	Asn	Pro	Lys	Thr	Thr	Thr	Thr	Thr	Thr	Thr	Lys	Ala	Ala	Thr
					50						55				60	
30	Thr	Thr	Lys	Ala	Pro	Val	Thr	Thr	Thr	Lys	Ala	Thr	Thr	Thr	Thr	Thr
					65					70				75		
35	Thr	Lys	Ala	Pro	Val	Thr	Thr	Thr	Lys	Ala	Thr	Thr	Thr	Thr	Thr	Thr
					80				85				90			
40	Lys	Thr	Thr	Thr	Lys	Thr	Thr	Thr	Thr	Lys	Ala	Ala	Thr	Thr	Thr	Ser
					95				100				105			
45	Ser	Ser	Asn	Thr	Gly	Tyr	Ser	Pro	Ile	Ser	Gly	Gly	Phe	Ser	Gly	Asn
					110				115				120			125
50	Gly	Arg	Thr	Thr	Arg	Tyr	Trp	Asp	Cys	Cys	Lys	Pro	Ser	Cys	Ala	Trp
					130					135					140	
55	Asp	Gly	Lys	Ala	Ser	Val	Thr	Lys	Pro	Val	Leu	Thr	Cys	Ala	Lys	Asp
					145					150				155		
60	Gly	Val	Ser	Arg	Leu	Gly	Ser	Asp	Val	Gln	Ser	Gly	Cys	Val	Gly	Gly
					160					165				170		
65	Gln	Ala	Tyr	Met	Cys	Asn	Asp	Asn	Gln	Pro	Trp	Val	Val	Asn	Asp	Asp
					175				180				185			
70	Leu	Ala	Tyr	Gly	Phe	Ala	Ala	Ala	Ser	Leu	Gly	Ser	Ala	Gly	Ala	Ser
					190					195			200			205

Ala Phe Cys Cys Gly Cys Tyr Glu Leu Thr Phe Thr Asn Thr Ala Val  
210 215 220  
Ala Gly Lys Lys Phe Val Val Gln Val Thr Asn Thr Gly Asp Asp Leu  
225 230 235  
Ser Thr Asn His Phe Asp Leu Gln Met Pro Gly Gly Gly Val Gly Tyr  
240 245 250  
Phe Asn Gly Cys Gln Ser Gln Trp Asn Thr Asn Thr Asp Gly Trp Gly  
255 260 265  
Ala Arg Tyr Gly Gly Ile Ser Ser Ile Ser Glu Cys Asp Lys Leu Pro  
270 275 280 285  
Thr Gln Leu Gln Ala Gly Cys Lys Trp Arg Phe Gly Trp Phe Lys Asn  
290 295 300  
Ala Asp Asn Pro Glu Val Thr Phe Lys Ala Val Thr Cys Pro Ala Glu  
305 310 315  
Ile Ile Ala Lys Thr Gly Cys Glu Arg Lys  
320 325

<210> 12  
<211> 1041  
<212> DNA  
<213> Phycomyces nitens CP99002

<220>  
<221> sig#peptide  
<222> (1)... (57)

<220>  
<221> mat#peptide  
<222> (58)... (1041)

5 <400> 12  
 atg aag ttc tcc atc atc gct tcc gcc ctt ctc ctc gct gcc agc tcc 48  
 Met Lys Phe Ser Ile Ile Ala Ser Ala Leu Leu Leu Ala Ala Ser Ser  
 10 -15 -10 -5  
 act tac gct gct gaa tgc agc caa ggc tat ggc cag tgt ggt ggc aag 96  
 Thr Tyr Ala Ala Glu Cys Ser Gln Gly Tyr Gly Gln Cys Gly Gly Lys  
 15 1 5 10  
 atg tgg act ggt ccc acc tgc tgc acc tcc gcc ttc acc tgt gta ggt 144  
 Met Trp Thr Gly Pro Thr Cys Cys Thr Ser Gly Phe Thr Cys Val Gly  
 20 15 20 25  
 gcc gaa aac aac gag tgg tac tct cag tgt atc ccc aac gat caa gtc 192  
 Ala Glu Asn Asn Glu Trp Tyr Ser Gln Cys Ile Pro Asn Asp Gln Val  
 25 30 35 40 45  
 cag ggt aac ccc aag acc acc acc acc acc acc acc aag gct gcc act 240  
 Gln Gly Asn Pro Lys Thr Thr Thr Thr Thr Thr Thr Thr Lys Ala Ala Thr  
 30 50 55 60  
 acc acc aag gct cct gtc acc acc acc aag gcc acc acc acc acc acc 288  
 Thr Thr Lys Ala Pro Val Thr Thr Thr Thr Lys Ala Thr Thr Thr Thr Thr  
 35 65 70 75  
 acc aag gcc cct gtc acc acc acc aag gcc act act act acc acc acc 336  
 Thr Lys Ala Pro Val Thr Thr Thr Thr Lys Ala Thr Thr Thr Thr Thr Thr  
 40 80 85 90  
 aag acc acc acc aag acc acc acc acc aag gct gcc acc acc acc tcc 384  
 Lys Thr Thr Thr Lys Thr Thr Thr Thr Thr Lys Ala Ala Thr Thr Thr Ser  
 45 95 100 105  
 tct tcc aac act ggc tac agc ccc att tct ggt ggc ttc tct gga aac 432  
 Ser Ser Asn Thr Gly Tyr Ser Pro Ile Ser Gly Gly Phe Ser Gly Asn  
 50 110 115 120 125  
 55

5 ggt cgc act acc cgc tac tgg gat tgc tgc aag ccc tct tgc gcc tgg 480  
 Gly Arg Thr Thr Arg Tyr Trp Asp Cys Cys Lys Pro Ser Cys Ala Trp  
 130 135 140  
 10 gac gga aag gct tct gta act aag cct gta ctc acc tgt gcc aag gat 528  
 Asp Gly Lys Ala Ser Val Thr Lys Pro Val Leu Thr Cys Ala Lys Asp  
 145 150 155  
 15 ggt gtc agc cgt ctc ggt tcc gat gtc cag agc ggt tgc gtc ggc ggc 576  
 Gly Val Ser Arg Leu Gly Ser Asp Val Gln Ser Gly Cys Val Gly Gly  
 160 165 170  
 20 cag gcc tac atg tgc aat gac aac cag ccc tgg gtt gtc aat gac gac 624  
 Gln Ala Tyr Met Cys Asn Asp Asn Gln Pro Trp Val Val Asn Asp Asp  
 175 180 185  
 25 ctt gcc tac ggt ttc gct gct gcc agt ctc ggt agc gcc ggt gcc tct 672  
 Leu Ala Tyr Gly Phe Ala Ala Ala Ser Leu Gly Ser Ala Gly Ala Ser  
 190 195 200 205  
 30 gca ttc tgc tgc ggc tgt tac gag ctt acc ttc acc aac act gct gtc 720  
 Ala Phe Cys Cys Gly Cys Tyr Glu Leu Thr Phe Thr Asn Thr Ala Val  
 210 215 220  
 35 gct ggc aag aag ttt gtc gtc cag gtc acc aac acc ggt gat gat ctc 768  
 Ala Gly Lys Lys Phe Val Val Gln Val Thr Asn Thr Gly Asp Asp Leu  
 225 230 235  
 40 agc acc aac cac ttt gat ttg cag atg ccc ggc ggt ggt gtc ggc tac 816  
 Ser Thr Asn His Phe Asp Leu Gln Met Pro Gly Gly Gly Val Gly Tyr  
 240 245 250  
 45 ttc aac ggc tgc cag tcc cag tgg aac acc aac acc gat ggc tgg ggt 864  
 Phe Asn Gly Cys Gln Ser Gln Trp Asn Thr Asn Thr Asp Gly Trp Gly  
 255 260 265  
 50 gct cgc tat ggc ggt att agc tct att tca gag tgc gac aag ctt cct 912  
 Ala Arg Tyr Gly Gly Ile Ser Ser Ile Ser Glu Cys Asp Lys Leu Pro  
 55

270                      275                      280                      285  
 5    acc cag ttg cag gct ggt tgc aag tgg aga ttc gga tgg ttc aag aac    960  
     Thr Gln Leu Gln Ala Gly Cys Lys Trp Arg Phe Gly Trp Phe Lys Asn  
                          290                      295                      300  
 10    gct gac aac cca gag gtc acc ttc aag gct gtt act tgc cct gcc gag    1008  
     Ala Asp Asn Pro Glu Val Thr Phe Lys Ala Val Thr Cys Pro Ala Glu  
                          305                      310                      315  
 15    atc att gcc aag act ggt tgc gag cgc aag taa                      1041  
     Ile Ile Ala Lys Thr Gly Cys Glu Arg Lys  
                          320                      325  
 20

<210> 13

<211> 1043

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-optimized sequence corresponding to RCE I  
 35        protein (SEQ. ID NO: 2)

<220>

<221> sig#peptide

<222> (16)... (84)

<220>

<221> mat#peptide

<222> (84)... (1043)

<400> 13

	ggatcctggg acaag atg aag ttc atc act atc gcc tcc tcc gcc ctc ctt	51
5	Met Lys Phe Ile Thr Ile Ala Ser Ser Ala Leu Leu	
	-20 -15	
	gcc ctc gcc ctt ggc act gag atg gcc tcc gcc gct gag tgc tcc aag	99
10	Ala Leu Ala Leu Gly Thr Glu Met Ala Ser Ala Ala Glu Cys Ser Lys	
	-10 -5 1 5	
	ctc tac gga cag tgc ggc gga aag aac tgg aac ggc ccc acc tgc tgc	147
15	Leu Tyr Gly Gln Cys Gly Gly Lys Asn Trp Asn Gly Pro Thr Cys Cys	
	10 15 20	
	gag agc ggc tgc acc tgc aag gtc tgc aat gac tac tac agc cag tgc	195
20	Glu Ser Gly Ser Thr Cys Lys Val Ser Asn Asp Tyr Tyr Ser Gln Cys	
	25 30 35	
	ctg ccg agc ggc tcc tgc gga aac aag tgc agc gag tgc gcc cac aag	243
25	Leu Pro Ser Gly Ser Ser Gly Asn Lys Ser Ser Glu Ser Ala His Lys	
	40 45 50	
	aag acc acg acc gct gcc cac aag aag acc acg acc gcc gct cac aag	291
30	Lys Thr Thr Thr Ala Ala His Lys Lys Thr Thr Thr Ala Ala His Lys	
	55 60 65	
	aag act acg acc gct ccc gcc aag aag acc acg acc gtc gcc aag gct	339
35	Lys Thr Thr Thr Ala Pro Ala Lys Lys Thr Thr Thr Val Ala Lys Ala	
	70 75 80 85	
	tgc act ccg tcc aac tgc agc agc tgc tct tgc gga aag tac agc gct	387
40	Ser Thr Pro Ser Asn Ser Ser Ser Ser Ser Ser Gly Lys Tyr Ser Ala	
	90 95 100	
	gtc agc ggt ggc gct agc ggc aac ggc gtc act acc cgc tac tgg gac	435
45	Val Ser Gly Gly Ala Ser Gly Asn Gly Val Thr Thr Arg Tyr Trp Asp	
	105 110 115	
	tgc tgc aag gct tgc tgc tgc tgg ccc ggc aag gct aac gtc agc tgc	483
50	Cys Cys Lys Ala Ser Cys Ser Trp Pro Gly Lys Ala Asn Val Ser Ser	

	120	125	130	
5	cct gtc aag tcc tgc aac aag gac ggc gtc acc gct ctt agc gac tcc			531
	Pro Val Lys Ser Cys Asn Lys Asp Gly Val Thr Ala Leu Ser Asp Ser			
	135	140	145	
10	aac gcc cag tcc ggc tgc aac ggc ggc aac tcc tac atg tgc aac gac			579
	Asn Ala Gln Ser Gly Cys Asn Gly Gly Asn Ser Tyr Met Cys Asn Asp			
	150	155	160	165
15	aac cag cca tgg gct gtc aac gac aac ctt gct tac ggt ttc gct gcc			627
	Asn Gln Pro Trp Ala Val Asn Asp Asn Leu Ala Tyr Gly Phe Ala Ala			
	170	175	180	
20	gct gcc att agc ggc ggt ggc gag agc cgc tgg tgc tgc tcc tgc ttc			675
	Ala Ala Ile Ser Gly Gly Gly Glu Ser Arg Trp Cys Cys Ser Cys Phe			
	185	190	195	
25	gag ctc acc ttc acc tcc acc agc gtt gct ggc aag aag atg gtc gtc			723
	Glu Leu Thr Phe Thr Ser Thr Ser Val Ala Gly Lys Lys Met Val Val			
	200	205	210	
30	cag gtc acc aac act ggc ggt gac ctt ggc agc tcg acc ggt gcc cac			771
	Gln Val Thr Asn Thr Gly Gly Asp Leu Gly Ser Ser Thr Gly Ala His			
	215	220	225	
35	ttc gat ctc cag atg ccc ggc ggc ggc gtc ggc atc ttc aac gga tgc			819
	Phe Asp Leu Gln Met Pro Gly Gly Gly Val Gly Ile Phe Asn Gly Cys			
	230	235	240	245
40	tcg tcc cag tgg ggc gct ccc aac gac ggc tgg ggc tcg cgc tac ggc			867
	Ser Ser Gln Trp Gly Ala Pro Asn Asp Gly Trp Gly Ser Arg Tyr Gly			
	250	255	260	
45	ggc atc agc tcc gcc agc gac tgc tcg tcc ctc ccc agc gcc ctc cag			915
	Gly Ile Ser Ser Ala Ser Asp Cys Ser Ser Leu Pro Ser Ala Leu Gln			
	265	270	275	
50	gcc ggc tgc aag tgg cgc ttc aac tgg ttc aag aac gcc gac aac ccg			963
55				

Ala Gly Cys Lys Trp Arg Phe Asn Trp Phe Lys Asn Ala Asp Asn Pro  
 280 285 290  
 5 tcc atg acc tac aag gag gtc acc tgc ccc aag gag atc acc gct aag 1011  
 Ser Met Thr Tyr Lys Glu Val Thr Cys Pro Lys Glu Ile Thr Ala Lys  
 10 295 300 305  
 acc gga tgc tgc cgc aag taa acgcagg atcc 1043  
 Thr Gly Cys Ser Arg Lys  
 15 310 315

<210> 14  
 20 <211> 40  
 <212> PRT  
 25 <213> Rhizopus oryzae CP96001

<400> 14  
 30 Ala Glu Cys Ser Lys Leu Tyr Gly Gln Cys Gly Gly Lys Asn Trp Asn  
 1 5 10 15  
 Gly Pro Thr Cys Cys Glu Ser Gly Ser Thr Cys Lys Val Ser Asn Asp  
 35 20 25 30  
 Tyr Tyr Ser Gln Cys Leu Pro Ser  
 35 40

<210> 15  
 45 <211> 22  
 <212> PRT  
 <213> Mucor circinelloides CP99001

<400> 15  
 50 Ala Ser Cys Ser Ser Val Tyr Gly Gln Cys Gly Gly Ile Gly Trp Ser  
 55



1                      5                      10                      15  
 Gly Pro Thr Cys Cys Glu  
 5                      20  
  
 10                      <210> 16  
                          <211> 23  
                          <212> PRT  
 15                      <213> *Phycomyces nitens* CP99002  
  
                          <400> 16  
 20                      Ala Glu Cys Ser Gln Gly Tyr Gly Gln Cys Gly Gly Lys Met Trp Thr  
                          1                      5                      10                      15  
 Gly Pro Thr Cys Cys Thr Ser  
 25                      20  
  
 30                      <210> 17  
                          <211> 39  
                          <212> PRT  
 35                      <213> Artificial Sequence  
  
                          <220>  
 40                      <223> Consensus amino acid sequence found in cellulose binding  
                          domains of the family 45 endoglucanases  
  
 45                      <220>  
                          <221> Xaa  
 50                      <222> (1).. (6), (11).. (14), (16).. (18), (20).. (25), (27).. (31),  
                          (33).. (34), (36), (39)  
                          <223> Xaa is one of all amino acids  
 55

5 <300>  
 <301> Hoffren, A. -M. et al.  
 <303> Protein Engineering  
 10 <304> 8  
 <306> 443-450  
 <307> 1995  
 15  
 <400> 17  
 Xaa Xaa Xaa Xaa Xaa Xaa Gln Cys Gly Gly Xaa Xaa Xaa Xaa Gly Xaa  
 20 1 5 10 15  
 Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Asn  
 25 20 25 30  
 Xaa Xaa Tyr Xaa Gln Cys Xaa  
 35  
 30  
 <210> 18  
 <211> 1257  
 35 <212> DNA  
 <213> Humicola insolens  
 40  
 <220>  
 <221> intron  
 <222> (453).. (509)  
 45  
 <400> 18  
 50 aatgacgggg caacctcccg cccgggcca acctctgggt ttggttgac aggccgtctg 60  
 tctcttgct cctcttacta cgcctgctg gacctacgt ctcaactccg attcaagaig 120  
 cgttctctcc ctctctccg ctccgccgtt gtggccgcc tgcgggtgtt ggcccttgcc 180  
 55

5      gctgatggca agtccaccog clactgggac tgcgtcaagc cticgtgagg clgggccaag 240  
 aaggctcccg tgaaccagcc tgccttctcc tgcaacgcca acttccagcg tctcactgac 300  
 ttcgacgcca agtccggctg cgagccgggc gggtcgcct actcgtgcgc cgaccagacc 360  
 ccatgggctg tgaacgacga cticgcgttc gggttgcgt ccacctctat tgcggcagc 420  
 10      aatgaggcgg gctgggtgctg gccttctac gagtaagctt tggtcgctg tgtaacactg 480  
 tgcaggcata gcactaacca cctcccaggc tcaccttacc atccggtcct gttgctggca 540  
 agaagatggt cgtccagtc accagcactg gcggtgatct tggcagcaac cacttcgac 600  
 15      tcaacatccc cggcggcggc gtggcatct tgcaggaag cactccccag ttcggcggtc 660  
 tgcccgcca gcgtacggc ggcatctct cccgcaacga gtgcgacgg tccccgacg 720  
 cctcaagcc cggctgctac tggcgcttc actggttcaa gaacgccgac aaccgagct 780  
 20      tcagcttccg tcaggtccaa tgcacggcg agctcgtgc tgcacccga tgcggccga 840  
 acgacgacgg caacttccc gccgtccaga tcccctccag cagcaccagc tctccggtc 900  
 25      gccagctac cagttaccag accacctcca cctccaccac ctgcagccc cccgtccagc 960  
 ctacgactcc cagcggctgc actgctgaga ggtgggtca gtgcggcggc aatggctgga 1020  
 gcggctgac cacttgcgt gcggcagca cctgcacga gattaatgac tggtaaccac 1080  
 30      agtgcctgta aacgcagggc agcctgagaa ccttactggt tgcgcaacga aatgacactc 1140  
 ccaatcactg tattagtct tttacataat ttcgtcacc ctccagggat tgcacatat 1200  
 atgcaatgat gaatactgaa cacaacctg gccgttgaa ctggccgaag gaatgcc 1257

35

&lt;210&gt; 19

&lt;211&gt; 1720

40

&lt;212&gt; DNA

<213> *Trichoderma viride*

45

&lt;220&gt;

&lt;221&gt; intron

50

&lt;222&gt; (500).. (682)

&lt;400&gt; 19

55

gggtgtgcat ttctccicaa catacigcct ttcaacaact ttgcctcct cctggcctg 60  
 atateccaat atcagttttt cccaaagtag caagtcacac gtaaatctgc tcatctatca 120  
 5 ttaatcagtg cccatagtggt ctgtctgttg attgcctccc gccatcacg atgaacagga 180  
 ccatggctcc attgtgtctt gcagcgtcga tactcttcgg gggcgtctgt gcacaacaga 240  
 10 ctgtctgggg acagtgtgga ggtattggtt ggagcggacc tacgagttgt gctcctggat 300  
 cagcttggtc tactctcaat ccttattatg cgcaatgcat tccgggggcc actagtatca 360  
 ccacctgcac cggaccccc tgggticcaa ccaccaccac cagagccacc tcaacgacct 420  
 15 catctccgcc accgaccagc tctggagttc gatttgcctg cgtaaacatc gcgggctttg 480  
 acttcggatg taccacagag tatgtcttca tgttgcatag tgttgcctgc tgagtattct 540  
 gggcggatga tttatagctg tgcggcgtgc aaaacaccgc cggctctcca ctatcaaggc 600  
 20 atagttgata ggcggcggtg tttcttcaa tccctgatt acactctcaa gaactagtg 660  
 gctgaiggtg gtagtattac agtggcactt gcgttacatc gaagtttat cctccgttga 720  
 agaactcac tggggcaaac aactaccggg acggtatcgg ccagatgcag cacttcgtca 780  
 25 acgatgatgg gatgactatt ttccgcctac ccgtcggatg gcagtaccic gtaaacacaa 840  
 atctgggtgg aactctcgal tccaccagta tctcgaagta tgcagctc gttcaggggt 900  
 gccgtctct cgggtatcac tgcacatcgc acatccacaa ttatgctcga tggaacggtg 960  
 30 gaalcatlgg ccaggagggc cctacaaatg cccagtttac cagcttttgg tgcagttgg 1020  
 catcgaagta cgcgtctcag tgcaggggtg ggttcggaat aatgaatgag ccccacgacg 1080  
 35 tgaacatcaa cacttgggtt gccacgggtc aagaggctgt cactgcaatc cgcaacgccg 1140  
 gtgtctacgc gcaatacatl tctctgcctg gaaatgatta tcaatctcgc gcagctttta 1200  
 ttccgatgg cagtgcagcc gccctgtctc aggtaacgaa cctgatgga tcaacaacga 1260  
 40 atctaactct cgatgtccac aagtacttag actcggacaa ctccggtact cagccgaat 1320  
 gcactacaaa caacatgcac ggcgcctttg ctccctcgc cacttggctt cgacagaaca 1380  
 accgccagcg tattctgacg gaaaccggcg gtggcaatgt tcagtcctgc atccaagatt 1440  
 45 tggccaaca gatccagtac ctcaaccaga actcagatgt ctatcttggc tatgttggct 1500  
 ggggtgccgg ttcatltagt agcacttata ttctgacgga aagcctact ggaagcggta 1560  
 50 actcgtggac ggacacatcc ctagttagct cgtgtctcgc caggaagtaa caccgaggic 1620  
 gattgcagga gccctgtcaa tagcgatttc atcttgcgt acataattct tactctctga 1680  
 agccgcttgt tctgggtatg tgtcttgaca ggttcttga 1720

55

**<210> 20**

**5 <211> 20**

**<212> DNA**

**10 <213> Artificial Sequence**

**<220>**

**15 <223> Description of Artificial Sequence:Primer**

**<400> 20**

**20 caccacgcgc tactgggact** **20**

**<210> 21**

**25 <211> 19**

**<212> DNA**

**30 <213> Artificial Sequence**

**<220>**

**35 <223> Description of Artificial Sequence:Primer**

**<400> 21**

**40 ggatccctgcg ttacttgc** **19**

**45 <210> 22**

**<211> 18**

**<212> DNA**

**50 <213> Artificial Sequence**

<220>

5 <223> Description of Artificial Sequence:Primer

<400> 22

10 ggatcctggg acaagatg 18

<210> 23

15 <211> 17

<212> DNA

20 <213> Artificial Sequence

<220>

25 <223> Description of Artificial Sequence:Primer

<400> 23

30 gcacgacggc ttgcagc 17

<210> 24

35 <211> 228

<212> PRT

40 <213> Artificial Sequence

<220>

45 <223> Description of Artificial Sequence:Recombinant  
protein

50 <400> 24

Met Gln Leu Pro Leu Thr Thr Leu Leu Thr Leu Leu Pro Ala Leu Ala

55 1 5 10 15

5	Ala Ala Gln Ser Gly Ser Gly Arg Thr Thr Arg Tyr Trp Asp Cys Cys	20	25	30
10	Lys Pro Ser Cys Ser Trp Pro Gly Lys Ala Asn Val Ser Ser Pro Val	35	40	45
15	Lys Ser Cys Asn Lys Asp Gly Val Thr Ala Leu Ser Asp Ser Asn Ala	50	55	60
20	Gln Ser Gly Cys Asn Gly Gly Asn Ser Tyr Met Cys Asn Asp Asn Gln	65	70	75
25	Pro Trp Ala Val Asn Asp Asn Leu Ala Tyr Gly Phe Ala Ala Ala Ala	85	90	95
30	Ile Ser Gly Gly Gly Glu Ser Arg Trp Cys Cys Ser Cys Phe Glu Leu	100	105	110
35	Thr Phe Thr Ser Thr Ser Val Ala Gly Lys Lys Met Val Val Gln Val	115	120	125
40	Thr Asn Thr Gly Gly Asp Leu Gly Ser Ser Thr Gly Ala His Phe Asp	130	135	140
45	Leu Gln Met Pro Gly Gly Gly Val Gly Ile Phe Asn Gly Cys Ser Ser	145	150	155
50	Gln Trp Gly Ala Pro Asn Asp Gly Trp Gly Ser Arg Tyr Gly Gly Ile	160		

	165	170	175
5	Ser Ser Ala Ser Asp Cys Ser Ser Leu Pro Ser Ala Leu Gln Ala Gly		
	180	185	190
10	Cys Lys Trp Arg Phe Asn Trp Phe Lys Asn Ala Asp Asn Pro Ser Met		
	195	200	205
15	Thr Tyr Lys Glu Val Thr Cys Pro Lys Glu Ile Thr Ala Lys Thr Gly		
20	210	215	220
	Cys Ser Arg Lys		
25	225		
30	<210> 25		
	<211> 20		
	<212> DNA		
35	<213> Artificial Sequence		
40	<220>		
	<223> Description of Artificial Sequence:Primer		
45	<400> 25		
	gcggatcctg ggacaagatg		20
50	<210> 26		
	<211> 24		
55	<212> DNA		



<213> Artificial Sequence

5

<220>

<223> Description of Artificial Sequence:Primer

10

<400> 26

gcctgcagag cggcggaggc catc

24

15

<210> 27

<211> 25

20

<212> DNA

<213> Artificial Sequence

25

<220>

<223> Description of Artificial Sequence:Primer

30

<400> 27

gcctgcaggg aaagtacagc gctgt

25

35

<210> 28

<211> 21

40

<212> DNA

<213> Artificial Sequence

45

<220>

<223> Description of Artificial Sequence:Primer

50

<400> 28

gcggatccctg cgattacttg c

21

55

<210> 29

<211> 245

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Recombinant  
protein

<400> 29

Met Lys Phe Ile Thr Ile Ala Ser Ser Ala Leu Leu Ala Leu Ala Leu

1

5

10

15

Gly Thr Glu Met Ala Ser Ala Ala Leu Gln Gly Lys Tyr Ser Ala Val

20

25

30

Ser Gly Gly Ala Ser Gly Asn Gly Val Thr Thr Arg Tyr Trp Asp Cys

35

40

45

Cys Lys Pro Ser Cys Ser Trp Pro Gly Lys Ala Asn Val Ser Ser Pro

50

55

60

Val Lys Ser Cys Asn Lys Asp Gly Val Thr Ala Leu Ser Asp Ser Asn

65

70

75

80

Ala Gln Ser Gly Cys Asn Gly Gly Asn Ser Tyr Met Cys Asn Asp Asn

85

90

95

5	Gln Pro Trp Ala Val Asn Asp Asn Leu Ala Tyr Gly Phe Ala Ala Ala	100	105	110
10	Ala Ile Ser Gly Gly Gly Glu Ser Arg Trp Cys Cys Ser Cys Phe Glu	115	120	125
15	Leu Thr Phe Thr Ser Thr Ser Val Ala Gly Lys Lys Met Val Val Gln	130	135	140
20	Val Thr Asn Thr Gly Gly Asp Leu Gly Ser Ser Thr Gly Ala His Phe	145	150	155
25	Asp Leu Gln Met Pro Gly Gly Gly Val Gly Ile Phe Asn Gly Cys Ser	165	170	175
30	Ser Gln Trp Gly Ala Pro Asn Asp Gly Trp Gly Ser Arg Tyr Gly Gly	180	185	190
35	Ile Ser Ser Ala Ser Asp Cys Ser Ser Leu Pro Ser Ala Leu Gln Ala	195	200	205
40	Gly Cys Lys Trp Arg Phe Asn Trp Phe Lys Asn Ala Asp Asn Pro Ser	210	215	220
45	Met Thr Tyr Lys Glu Val Thr Cys Pro Lys Glu Ile Thr Ala Lys Thr	225	230	235
50				240
55	Gly Cys Ser Arg Lys	245		

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

<210> 30  
<211> 7  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence:N-terminus  
sequence of recombinant protein  
  
<400> 30  
Gln Ser Gly Ser Gly Arg Thr  
1 5  
  
<210> 31  
<211> 7  
<212> PRT  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence:N-terminus  
sequence of recombinant protein  
  
<400> 31  
Lys Tyr Ser Ala Val Ser Gly  
1 5

<210> 32

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:N-terminus  
sequence of recombinant protein

<400> 32

Ala Val Ser Gly Gly Ala Ser

1 5

<210> 33

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:N-terminus  
sequence of recombinant protein

<400> 33

Ser Ala Val Ser Gly Gly Ala

1 5

<210> 34

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:N-terminus  
sequence of recombinant protein

<400> 34

Gly Gly Ala Ser Gly Asn Gly

1 5

<210> 35

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:N-terminus  
sequence of recombinant protein

<400> 35

Ala Glu Cys Ser Lys Leu Tyr

1 5

<210> 36

&lt;211&gt; 20

## <212> DNA

### <213> Artificial Sequence

**<220>**

### <223> Description of Artificial Sequence:Primer

**<400> 36**

taytgggayt gytgyaarcc

20

**<210> 37**

&lt;211&gt; 20

## <212> DNA

### **<213> Artificial Sequence**

**<220>**

### <223> Description of Artificial Sequence:Primer

**<220>**

<221> modified#base

**<222> (3)**

**<223> i**

**<220>**

<221> modified#base

**<222> (9)**

&lt;223&gt; i

<400> 37

tcngcrtina rraaccaric

20

5

&lt;210&gt; 38

10

&lt;211&gt; 223

&lt;212&gt; PRT

&lt;213&gt; Humicola insolens

15

&lt;400&gt; 38

20

Met Gln Leu Pro Leu Thr Thr Leu Leu Thr Leu Leu Pro Ala Leu Ala

1 5 10 15

25

Ala Ala Gln Ser Gly Ser Gly Arg Thr Thr Arg Tyr Trp Asp Cys Cys

20 25 30

30

Lys Pro Ser Cys Ala Trp Pro Gly Lys Gly Pro Ala Pro Val Arg Thr

35 40 45

35

Cys Asp Arg Trp Asp Asn Pro Leu Phe Asp Gly Gly Asn Thr Arg Ser

50 55 60

40

Gly Cys Asp Ala Gly Gly Gly Ala Tyr Met Cys Ser Asp Gln Ser Pro

65 70 75 80

45

Trp Ala Val Ser Asp Asp Leu Ala Tyr Gly Trp Ala Ala Val Asn Ile

85 90 95

50

Ala Gly Ser Asn Glu Arg Gln Trp Cys Cys Ala Cys Tyr Glu Leu Thr

55

100 105 110



5 Phe Thr Ser Gly Pro Val Ala Gly Lys Arg Met Ile Val Gln Ala Ser  
115 120 125

10 Asn Thr Gly Gly Asp Leu Gly Asn Asn His Phe Asp Ile Ala Met Pro  
130 135 140

15 Gly Gly Gly Val Gly Ile Phe Asn Ala Cys Thr Asp Gln Tyr Gly Ala  
145 150 155 160

20 Pro Pro Asn Gly Trp Gly Gln Arg Tyr Gly Gly Ile Ser Gln Arg His  
165 170 175

25 Glu Cys Asp Ala Phe Pro Glu Lys Leu Lys Pro Gly Cys Tyr Trp Arg  
180 185 190

30 Phe Asp Trp Phe Leu Asn Ala Asp Asn Pro Ser Val Asn Trp Arg Gln  
195 200 205

35 Val Ser Cys Pro Ala Glu Ile Val Ala Lys Ser Gly Cys Ser Arg  
40 210 215 220

45 <210> 39

<211> 672

<212> DNA

50

<213> Humicola insolens

55 <400> 39

atgcagctcc cccctgaccac gctccctcacc ctccctccccg cccctcgcgge ggcccagctcc 60  
 5 ggcagcggcc gcaccacgcg ctactgggac tgcctgaagc cgtcgtgcgc gtggcccggc 120  
 aaggggcccg cgcccgtgcg gacgtgcgac cggctgggaca acccgctggt cgacggcgge 180  
 aacacgcgca gcgggltcga cgcggcgggc ggcgcttaca tglgtcggc ccagagcccc 240  
 10 tggcggttca gcgacgacct ggcgctacggc tggcgggccg tcaacattgc cggctccaac 300  
 gagaggcagt ggtgtcgcgc ctgctacgag ctgaccttca ccagcgggcc ggtggcgggc 360  
 aagaggatga ttgtgcaggc gagcaacacg ggaggcgatt tggggaacaa ccactttgat 420  
 15 attgctatgc ccggcgggtg cgtcgggtac ttcaacgcct gcaccgacca gtacggcgcg 480  
 ccccccaacg gctggggcca gcgctacggc ggcatcagcc aacgccacga gtgcgacgcc 540  
 20 ttccccgaga agctcaagcc cggctgctac tggcgcttgc aciggttct caacgccgac 600  
 aacccgagcg tcaactggcg gcaggtcagc tggccggccg agattgtggc caagagcggc 660  
 tgctcgcggt aa 672

25

&lt;210&gt; 40

&lt;211&gt; 38

30

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

35

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:Primer

40

&lt;400&gt; 40

ggggatccctg ggacaagatg cagctcccc tgaccacg

38

45

&lt;210&gt; 41

&lt;211&gt; 38

50

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

55

<220>

<223> Description of Artificial Sequence:Primer

5

<400> 41

10

ggggatccg catttaacgc gagcagccgc tcttgcc

38

<210> 42

15

<211> 21

<212> DNA

<213> Artificial Sequence

20

<220>

<223> Description of Artificial Sequence:Primer

25

<400> 42

30

gactgctgca agccgtcgtg c

21

<210> 43

35

<211> 20

<212> DNA

<213> Artificial Sequence

40

<220>

<223> Description of Artificial Sequence:Primer

45

<400> 43

50

gllgcacatg taggagttgc

20

55

Claims

1. A protein that is a *Zygomycetes*-derived endoglucanase lacking the cellulose-binding domain and exhibits endoglucanase activity.
2. A protein that is a *Zygomycetes*-derived endoglucanase belonging to family 45 lacking the cellulose-binding domain and exhibits endoglucanase activity.
3. The protein according to claim 1 or 2, wherein the *Zygomycetes* are microorganisms selected from the group consisting of those belonging to *Rhizopus*, *Mucor*, and *Phycomyces*.
4. The protein according to claim 3, wherein the *Zygomycetes* are microorganisms belonging to *Rhizopus*.
5. A protein comprising an amino acid sequence as shown in SEQ ID NO: 1, 3, 5, 7, 9, or 11, wherein the cellulose-binding domain has been deleted therefrom, and exhibiting endoglucanase activity, a modified protein thereof exhibiting endoglucanase activity, or a homologue of the protein or the modified protein exhibiting endoglucanase activity.
6. A protein comprising an amino acid sequence as shown in SEQ ID NO: 1, 3, 5, 7, 9, or 11, wherein the cellulose-binding domain has been deleted therefrom, and exhibiting endoglucanase activity.
7. A gene encoding the protein, modified protein thereof, or homologue of the protein or the modified protein according to any one of claims 1 to 6.
8. An expression vector comprising the gene according to claim 7.
9. A host cell transformed with the expression vector according to claim 8.
10. The host cell according to claim 9, which is a filamentous fungus.
11. The host cell according to claim 10, which is a microorganism belonging to *Humicola*.
12. A method for producing a protein comprising steps of culturing the host cell according to any one of claims 9 to 11 and collecting from the host cell obtained by the step of culturing or its culture product the protein, modified protein thereof, or homologue of the protein or the modified protein according to any one of claims 1 to 6.
13. A protein produced by the method according to claim 12.
14. A cellulase preparation comprising the protein, modified protein thereof, or homologue of the protein or the modified protein according to any one of claims 1 to 6 and 13.
15. A method for treating cellulose-containing fabrics comprising a step of bringing cellulose-containing fabrics into contact with the protein, modified protein thereof, or homologue of the protein or the modified protein according to any one of claims 1 to 6 and 13 or the cellulase preparation according to claim 14.
16. A method for reducing the rate at which cellulose-containing fabrics become fuzzy or reducing fuzzing in cellulose-containing fabrics comprising a step of bringing cellulose-containing fabrics into contact with the protein, modified protein thereof, or homologue of the protein or the modified protein according to any one of claims 1 to 6 and 13 or the cellulase preparation according to claim 14.
17. A method of weight loss treatment of cellulose-containing fabrics to improve the feel and appearance thereof comprising a step of bringing cellulose-containing fabrics into contact with the protein, modified protein thereof, or homologue of the protein or the modified protein according to any one of claims 1 to 6 and 13 or the cellulase preparation according to claim 14.
18. A method of color clarification of colored cellulose-containing fabrics comprising a step of treating colored cellulose-containing fabrics with the protein, modified protein thereof, or homologue of the protein or the modified protein according to any one of claims 1 to 6 and 13 or the cellulase preparation according to claim 14.

19. A method of providing colored cellulose-containing fabrics with partial color change comprising a step of treating colored cellulose-containing fabrics with the protein, modified protein thereof, or homologue of the protein or the modified protein according to any one of claims 1 to 6 and 13 or the cellulase preparation according to claim 14.
- 5 20. A method for reducing the rate at which cellulose-containing fabrics become stiff or reducing stiffness in cellulose-containing fabrics comprising a step of treating cellulose-containing fabrics with the protein, modified protein thereof, or homologue of the protein or the modified protein according to any one of claims 1 to 6 and 13 or the cellulase preparation according to claim 14.
- 10 21. The method according to any one of claims 15 to 20, wherein fabrics are treated through the soaking, washing, or rinsing thereof.
- 15 22. An additive to detergent comprising the protein, modified protein thereof, or homologue of the protein or the modified protein according to any one of claims 1 to 6 and 13 or the cellulase preparation according to claim 14 in a non-dusting granular form or a stabilized liquid form.
- 20 23. A detergent composition comprising the protein, modified protein thereof, or homologue of the protein or the modified protein according to any one of claims 1 to 6 and 13 or the cellulase preparation according to claim 14.
- 25 24. A method of deinking waste paper using a deinking agent wherein the protein, modified protein thereof, or homologue of the protein or the modified protein according to any one of claims 1 to 6 and 13 or the cellulase preparation according to claim 14 is used in a step of deinking waste paper.
- 25 25. A method for improving drainage of paper pulp comprising a step of treating paper pulp with the protein, modified protein thereof, or homologue of the protein or the modified protein according to any one of claims 1 to 6 and 13 or the cellulase preparation according to claim 14.
- 30 26. A method for improving digestibility of animal feeds comprising a step of treating animal feeds with the protein, modified protein thereof, or homologue of the protein or the modified protein according to any one of claims 1 to 6 and 13 or the cellulase preparation according to claim 14.

35

40

45

50

55

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP01/10188

## A. CLASSIFICATION OF SUBJECT MATTER

Int.Cl.<sup>7</sup> C12N 15/56, 1/15, 9/42, C11D 3/386, D06M 16/00 // (C12N 15/56, C12R 1:845), (C12N 15/56, C12R 1:645), (C12N 15/56, C12R 1:785), (C12N 1/15, C12R 1:645), (C12N 9/42, C12R 1:645), D06M101:06

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int.Cl.<sup>7</sup> C12N 15/00-15/90, 9/42

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

MEDLINE (STN), WPI (DIALOG), BIOSIS (DIALOG), GenBank/EMBL/DBJ/GeneSeq, SwissProt/PIR/GeneSeq

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	AZEVEDO, H. et al., "Effects of agitation level on the adsorption, desorption, and activities on cotton fabrics of full length and core domains of EGV ( <i>Humicola insolens</i> ) and CenA ( <i>Cellulomonas fimi</i> ).", Enzyme Microb. Technol., August, 2000, Vol.27, No.3-5, pages 325 to 329	1-26
Y	WO 00/24879 A1 (Meiji Seika Kaisha, Ltd.), 04 May, 2000 (04.05.2000), & AU 9962300 A & EP 1123974 A1	1-26
P,A	WO 01/90375 A1 (Meiji Seika Kaisha, Ltd.), 29 November, 2001 (29.11.2001), (Family: none)	1-26
A	WO 94/21801 A2 (Genencor International, Inc.), 29 September, 1994 (29.09.1994), & FI 9504330 A & US 5475101 A & EP 689598 A1 & US 5753484 A	1-26

☒ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance  
 "E" earlier document but published on or after the international filing date  
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  
 "O" document referring to an oral disclosure, use, exhibition or other means  
 "P" document published prior to the international filing date but later than the priority date claimed

"I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  
 "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  
 "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art  
 "&" document member of the same patent family

Date of the actual completion of the international search  
 07 February, 2002 (07.02.02)

Date of mailing of the international search report  
 26 February, 2002 (26.02.02)

Name and mailing address of the ISA/  
 Japanese Patent Office

Authorized officer

Facsimile No.

Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP01/10188

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	TAKASHIMA, S. et al., "Comparison of gene structures and enzymatic properties between two endoglucanases from <i>Humicola grisea</i> ", J. Biotechnol., (1999), Vol. 67, No. 2-3, pages 85 to 97	1-26

Form PCT/ISA/210 (continuation of second sheet) (July 1992)